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1 General Introduction 
1.1 G protein coupled receptors 
1.1.1 Preliminary remarks 
G protein coupled receptors (GPCRs) are the largest known gene family of the 
human genome and the most versatile class of cell surface proteins. A wide range of 
extracellular messengers such as biogenic amides, lipids, peptides and proteins, 
odorants and tastants, hormones, neurotransmitters, ions and even photons exert 
their signals through GPCRs. With specific manipulation of GPCR signaling a diverse 
array of physiological and pathophysiological processes can be modified and 
therefore GPCRs are of high therapeutic value for existing and emerging drug 
therapies. All GPCRs share a common structural architecture consisting of seven 
transmembrane (7-TM) segments that are connected by extracellular and 
intracellular loops (Fredriksson et al., 2003). The 7-TM domain is framed by an 
extracellular N-terminus and an intracellular C-terminus. Classically, the GPCRs 
mediate signals by coupling to heterotrimeric G proteins, but it became increasingly 
apparent that they can also transduce signals through other proteins (Rajagopal et 
al., 2005). As a consequence of these G protein independent mechanisms, it is 
actually recommended to replace the term GPCR by “7-TM receptor” or “serpentine 
receptor”, but the GPCR terminology is more established. Nevertheless, GPCRs can 
generally be grouped into six main families which are Class A Rhodopsin-like 
receptors, Class B Secretin-like receptors, Class C Metabotropic glutamate 
receptors, Class D Pheromone receptors, Class E cAMP receptors and Class F 
Frizzled/smoothening family (Horn et al., 2003).   
1.1.2 GPCR activation 
Binding of an agonist to a GPCR induces a conformational change of the 
receptor. This conformation leads to an interaction with heterotrimeric G proteins 
accompanied by the release of bound GDP which is immediately replaced by GTP 
(see Figure 1.1). Bound GTP reduces affinity of the Gα subunit to Gβγ and provokes 
dissociation of the Gα-GTP-Gβγ complex into the subunits Gα-GTP and Gβγ. Both 
subunits can regulate specific effector systems depending on the associated Gα 
subunit (see below). Deactivation of the G protein is accomplished by the intrinsic 
GTPase activity of the Gα subunit, cleaving GTP to GDP and Pi. This step of the G 
protein cycle can be catalyzed by GTPase accelerating proteins (GAPs), also called 
  
regulators of G protein signaling (RGS) proteins. Subsequently, reassociation of G
GDP and Gβγ completes the G protein cycle and the initial state is restored.
 
 
 
Figure 1.1: G protein activation of GPCRs 
Activation cycle of heterotrimeric G protein after stimulation by an agonist (adapted from Seifert and 
Wieland, 2005) 
 
The intracellular effects of GPCR activation is mediated by four classes of 
heterotrimeric G proteins. Thi
Gα subunit. Gαs subunits stimulate and G
which leads to altered cyclic 3´,5´
Gαq/11 subunits activate phospholipase C
of phosphatidyl-inositol-4,5
inositol-1,4,5-triphosphat (IP
nucleotide exchange factors resulting in the regulat
al., 2008). All second messengers
modulation of intracellular ion concentration or altered enzyme activity or, as long 
term effect, induce regulation of gene expression by modulating transcription factors. 
Moreover, activated Gβγ subunits have also the ability
(Birnbaumer, 2007). 
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s classification is based on sequence homology of the 
αi/o subunits inhibit adenyly cyclase activity 
-adenosine monophosphate (cAMP) production. 
 (PLC) β and thereby catalyze the hydrolysis 
-diphosphat (PIP2) to 1,2-diacylglycerol (DAG) and 
3). Gα12/13 subunits are shown to interact with guanine 
ion of RhoA activity 
 are able to cause fast responses such as 
 to affect effector systems 
α, 
 
 
  
(Worzfeld et 
 Summarized, the G protein signal cascade is influ
interaction of a ligand with the receptor, transduction of the signal to the 
heterotrimeric G proteins, interaction of the activated G proteins with effector systems 
and, finally, inactivation of G proteins.
1.1.3 The two-state activation model of GPCRs
For illustration of pharmacological properties 
two-state model is often referred (see Figure
active and in an inactive state, which are equilibrated 
2003). A receptor in the active state (R*) is able to bind a G Protein and to initiate the 
intracellular signaling machinery. The inactive state of the receptor (R) marginally 
interacts with G proteins and thus hardly causes the exchange of GDP to GTP. An 
agonist stabilizes the active form of the receptor, whereas a compound that st
the inactive state is called inverse agonist. A neutral antagonist does not change the 
equilibrium, but occupies the binding site at the GPCR and blocks thereby agonist 
and inverse agonist effects. Partial agonists or inverse agonists have, relative to a full 
agonist or inverse agonist, lower capabilities to activate or inhibit 
Interestingly, some receptors occur in the active state without a
attribute is called constitutive activity and is often observed among GPCRs 
and Wenzel-Seifert, 2003). 
 
inverse 
agonist 
partial
 inverse 
agonist
Figure 1.2: Two-state model of GPCR activation 
Receptors can adopt an active (R*) and an inactive conformation (R). Ligands are characterized 
according to their ability to shift the equilibrium to either side of both states 
Seifert, 2003). 
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Observations of agonist-specific trafficking of a receptor stimulus refined the 
two-state model. In accordance with this model, each agonist is capable of stabilizing 
or selecting a unique receptor conformation. This phenomenon results in an unlimited 
number of active receptor states (Kenakin, 1995; Urban et al., 2007). Each of these 
conformations can interact highly selective with specific intracellular signaling 
complexes. Receptors with this functional selectivity likely form the basis for a new 
strategy of drug development. Screening for novel ligands would not only include 
binding affinity studies or evaluation of agonist/inverse agonist properties, but also 
studies on activation of the receptor connected to specific and appropriate 
intracellular response. 
1.1.4  Fusion proteins 
The first GPCR-Gα fusion protein was described in 1994, when Bertin et al. 
reported the successful fusion of the β adrenergic receptor with Gαs (Bertin et al., 
1994). This construct, expressed in S49 lymphoma cells, induced a greater 
stimulation of cAMP with an increase in potency compared to wild-type cells. These 
effects were suggested to be caused by a more efficient coupling between receptor 
and G protein. As the efficiency of receptor–G protein interaction is influenced by the 
protein expression levels, a clear advantage of the fusion approach is the defined 1:1 
stoichiometry together with a close proximity of the signaling partners, both firmly 
anchored in the plasma membrane (Seifert et al., 1999). Initially, it was hypothesized 
that fusion of a GPCR to a Gα leads to a functional interaction no matter whether the 
subunit is appropriate or not. This proximity-induced loss of G protein selectivity 
would have been a great opportunity to study orphan receptors or GPCRs coupled to 
Gαs or Gαq for which the agonist-regulated guanine nucleotide exchange is more 
difficult to measure. Unfortunately several studies revealed that this is not the case. 
Co-expression of Gαi with the IP prostanoid receptor, a Gαs coupled GPCR, did not 
result in activation of G protein and the use of the IP-Gαi fusion protein did not 
revealed any effect (Fong and Milligan, 1999). However, the fusion approach is an 
elegant way to study receptor-G protein interaction with a guaranteed lack of receptor 
reserve and thus an useful tool to explore the basis of ligand efficacy and to measure 
effects of point mutations in GPCR and G proteins (Colquhoun, 1998; Milligan, 2000).  
Another area of application concerning fusion proteins is the examination of 
homo- and heterodimerisation of GPCRs. As it is known many GPCRs can form 
dimers or oligomers with co-expressed receptors in a homologous or heterologous 
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manner (Milligan, 2007). For these studies two fusion proteins are constructed that 
are both inactive when expressed individually because of specific mutations. 
Mutations in the highly conserved hydrophobic residue in the second intracellular 
loop of a GPCR to acidic residues generate receptors that do not transmit the signal 
to the G protein or are simply unable to bind an agonist. This receptor is fused to a 
wild-type Gα subunit. Another or the same wild-type receptor is fused to a G protein 
unable to promote GCP/GTP exchange and hence activation. To induce inactivity of 
G proteins, Gly202 is mutated to Ala. These constructs are co-transfected and by 
measuring reconstitution of function, conclusions can be drawn on their interactions 
concerning homo- and heterodimerisation (Milligan et al., 2005). 
Despite some reported exceptions (Dupuis et al., 1999), the use of fusion 
proteins can increase signal-to-background ratio. The higher sensitivity compared to 
the Gα co-transfection systems makes the fusion protein approach to an interesting 
tool for ligand screening assays. Also, for the characterization of orphan receptors 
fusion proteins are applied (Guo et al., 2001; Takeda et al., 2003). As mentioned 
above, a set of GPCR-G protein fusions must be constructed to evaluate the effect of 
a ligand or to ensure the lack of effect through a specific receptor.  
GPCR-G fusion proteins may not exactly reflect the physiological situation as 
we still do not know to how many G proteins one single receptor has access to. But 
as the efficacy of receptor-G protein interaction depends on their expression levels, 
the fixed stoichiometry and the forced proximity in the cell membrane make the 
fusion approach to an attractive and precious tool for the above mentioned fields of 
research. 
1.1.5 RGS proteins 
G protein signaling is determined by the intrinsic GTPase activity, hydrolyzing 
bound GTP in GDP and Pi, which then induces reassociation of the α and βγ subunits 
and the return to the basal receptor state. The activity of GTPase can be influenced 
by specific proteins that are consequently called regulators of G protein signaling 
(RGS). These RGS proteins are able to act as GTPase accelerating proteins (GAPs) 
and terminate signaling of Gα subunits through reducing maximal or steady-state 
levels of active G proteins. Among the more than 20 known RGS with GAP activity 
only for Gαs no RGS interaction partner has been confirmed yet, whereas all other 
interact with Gαi and/or Gαq class of G proteins. The ability of RGS protein to act as 
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GAPs is due to a highly conserved region of approximately 120 amino acids termed 
as the RGS domain, that can interact with Gα subunits (Popov et al., 1997).  
Increasing evidence showed that RGS proteins are involved in more cellular 
functions beyond shortening the time in which the Gα subunit stay in its active 
conformation. RGS proteins can interact with additional cellular molecules such as 
receptors, effectors and scaffolds. These interactions are on the one hand important 
for GAP effects and show on the other hand that RGS proteins are involved in many 
cellular mechanisms playing diverse functional roles in living cells (Abramow-Newerly 
et al., 2006). The interactions are not exclusively served by the RGS domain but by 
additional domains being part of many RGS proteins (Sethakorn et al., 2010). Due to 
their link to other proteins and signaling pathways as well as for their ability to 
shorten G protein signaling, RGS proteins are interesting new pharmacological 
targets (Sjogren et al., 2010). In the following, two RGS proteins will be presented in 
more detail. 
1.1.5.1  RGS4 
RGS4 belongs to the B/R4 subfamily of RGS proteins and is a relatively small 
molecule which is selectively enriched in CNS and heart (Bowden et al., 2007; Cifelli 
et al., 2008). As described by Zeng et al. (1998) the N-terminal domain of the RGS4 
protein is implicated in GPCR binding as deletion of this region reduces the ability of 
RGS4 to modulate GPCR signaling. This provided indication that the modulation of a 
G protein signal depends on the activating receptor and that the receptors regulate 
affinity of RGS4 proteins to the G protein.  
Several studies showed that RGS4 is involved into the generation of several 
diseases. As an example it is thought that RGS4 is an important factor in breast 
cancer metastasis (Xie et al., 2009) and a genetic biological marker of schizophrenia 
(Bowden et al., 2007). Furthermore, RGS4 is essential for cardiac adaption (Cifelli et 
al., 2008) and has been shown to control critical signal events that are contributed to 
addictive processes such as opiate dependence (Hooks et al., 2008). 
1.1.5.2 RGS19 
Members of the A/RZ subfamily of RGS proteins are quiet similar in size to the 
members of the B/R4 subfamily but differ in the N-terminal regions, containing a 
cysteine string motif for palmitoylation and thereby anchoring RGS protein to the 
membrane. RGS19, or also called Gα interacting protein (GAIP), is a prominent 
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member of this subfamily and contains an additional C-terminal PDZ binding motif. 
This for RGS protein unique C-terminus seems to be crucial for the recruitment of 
RGS19 activity. De Vries et al. (1998), reported the isolation and characterization of a 
protein, named GIPC (GAIP interaction protein C-terminus), that interacts with its 
PDZ domain with RGS19. As it was demonstrated that GIPC can also specifically 
bind to GPCR, it is assumed that GIPC can act as an adapter protein between 
receptor and RGS19. This was recently confirmed for the dopamine D2 receptor 
(Jeanneteau et al., 2004b). 
Up to now, physiological functions of RGS19 are related to signal determination 
(Hepler et al., 1997; Jeanneteau et al., 2004a) and cell proliferation (Tso et al., 2010) 
but further investigations have to be done to clarify its mechanism of action. 
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1.2 The endocannabinoid system 
1.2.1 Cannabinoid receptors, endogenous ligands and involved enzymes 
The endocannabinoid system (ECS) comprises cannabinoid receptors (CBRs), 
various endocannabinoids and enzymes for endogenous ligand biosynthesis and 
inactivation. So far, two human CBRs have been identified. The CB1R was cloned in 
1990 (Matsuda et al., 1990) and is the most abundant GPCR in the central nervous 
system (CNS), but is also present in several peripheral tissues, such as the 
gastrointestinal tract, the cardiovascular and reproductive systems (Svizenska et al., 
2008), as well as in liver, pancreas, adipocytes, lung and skeletal muscle (Pacher et 
al., 2006). The CB2R, cloned in 1993 (Munro et al., 1993), is mostly restricted to 
immune tissues (Berdyshev, 2000; Cabral et al., 2008), osteoclasts and osteoblasts 
(Bab and Zimmer, 2008). In contrast to the CB1R, the N-terminal domain of CB2R is 
much shorter. The overall homology of the CB1R and the CB2R is about 44%, which 
increases up to about 68% in the TM domains (Lutz, 2002). 
The discovery of the specific receptors initiated research on the identification of 
endogenous ligands, so called endocannabinoids. The first and major 
endocannabinoids discovered were anandamide (Devane et al., 1992), the amide of 
arachidonic acid and ethanolamine, and 2-arachidonoyl glycerol (2-AG) (Mechoulam 
et al., 1995; Sugiura et al., 1995). Further less investigated endocannabinoids are 2-
arachidonyl glycerol ether (noladin ether) (Hanus et al., 2001) and N-arachidonoyl 
dopamine (Bisogno et al., 2000), both agonists at the CB1R, and O-arachidonoyl 
ethanolamine (virodhamin) with CB1R antagonistic properties (Porter et al., 2002). 
More recently, the first endogenous compound interacting with CBRs that is not 
derived from membrane lipids was discovered. Hemopressin was identified as a 
peptide ligand with inverse agonist effects at  CB1R (Heimann et al., 2007). Whether 
this nonapepide is an endogenous ligand has to be verified. 
The metabolism pathways of anandamide and 2-AG have been largely 
investigated but are not yet fully understood (Di Marzo, 2009). The main biosynthetic 
route is through on-demand hydrolysis of precursors present in the cytoplasm 
membrane. The synthesis of anandamide is catalyzed by N-acylphosphatidyl 
ethanolamine specific phospholipase D (Okamoto et al., 2004). For 2-AG two sn-1-
selective diacylglycerol lipases are confessed (Bisogno et al., 2003). The inactivation 
of anandamide is mostly actuated by intracellular cleavage of the amide structure by 
the fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996). This enzyme can also 
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catalyze 2-AG hydrolysis, but additional hydrolases for 2-AG degradation are known 
such as monoaclyglycerol lipase (MAGL) (Dinh et al., 2002). Furthermore, beside the 
hydrolytic metabolism of endocannabinoids, an oxidative degradation via oxygenases 
including COX and LOX is assumed (Kozak and Marnett, 2002).  
The enzymes for endocannabinoid biosynthesis and inactivation as well as 
cellular transporters for the release and uptakes of ligands and of course the CBRs 
are important pharmacological tools for the modulation of ECS activity. 
1.2.2 Cannabinoid signaling  
Both human CBRs are belonging to family A of GPCRs (Howlett et al., 2002) 
and are mostly coupled to Gαi/o. This interaction consequently leads to inhibition of 
adenylyl cyclase with reduction in cAMP accumulation. Both receptors regulate the 
activation of mitogen-activated protein (MAP) kinase and stimulation of the receptors 
is coupled to PLC activation resulting in a subsequent release of Ca2+ from internal 
stores.  
In contrast to the CB2R, the CB1R is able to interact with ion channels. For 
CB1Rs, inhibition of voltage gated Ca2+ channels as well as activation of A type and 
inwardly rectifying K+ channels are reported (Bosier et al., 2010; Demuth and 
Molleman, 2006).  
Evidence suggests that agonists at both CBRs can activate one single signaling 
pathway over another (Shoemaker et al., 2005; Bosier et al., 2007) – a phenomenon 
that is already described for other GPCRs (Urban et al., 2007). This functional 
selectivity offers the great possibility to identify new CBR ligands that regulate a 
specific signaling pathway. Particularly in the case of CBRs that modulate multiple 
physiological functions (see Chapter 1.2.4), novel therapeutic applications without 
psychoactive side effects might be conceivably.  
The ability of cannabinoids to modulate the activity of other receptor types or 
their signal transduction pathways has been demonstrated. For example, 
experiments revealed that the release of opioids is elevated by administration of ∆9-
THC (Parolaro et al., 2010). Also, the encephalin and dynorphin biosynthesis can be 
modulated by cannabinoids (Corchero et al., 1997). The synergistic effect of 
cannabis and the endomorphic system with respect to antinociception is an 
interesting target for pain therapy. 
For anandamide and other CBR ligands, interactions with the orphan receptor 
GPR55 (Ryberg et al., 2007), the transient receptor potential vanilloid 1 receptor 
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TRPV1 (Smart et al., 2000), as well as with serotonin 5-HT3 (Barann et al., 2002) and 
N-methyl-D-aspartate receptor NMDA (Hampson et al., 1998) were reported, 
showing that the behavioral effects of the (endo-)cannabinoids do not occur 
exclusively through the CBRs but also through interactions with other signaling 
systems. 
1.2.3 In-vitro bioassay systems for CBRs 
In-vitro test are often designed for screening procedures, to investigate receptor 
pharmacology and/or to explore the molecular mechanisms of action of a compound. 
Most common assays are cell based and measure downstream effects of the signal 
cascade. For the CBRs the most widely used in-vitro assays are competition binding 
assays, [35S]GTPγS binding experiments or – at more distal points -  measurement of 
cAMP production and inhibition of electrically evoked contractions of isolated smooth 
muscle preparations. 
For binding assays, radiolabeled CBR ligands as [3H]CP 55,940, [3H]HU-243 or 
[3H]WIN 55,212-2 are commonly used (Howlett et al., 2002). In this type of assay the 
radiolabeled probe competes with the test compound for binding to the CBRs and the 
amount of bound radioligand can be measured. This allows a conclusion on the 
affinity of the tested compound. However, no statements on the pharmacological 
properties of the tested ligand can be deducted. 
The [35S]GTPγS binding measures the coupling of G protein to CBRs at a very 
early step of the signal cascade following receptor occupation by a ligand. In case of 
occupation by an agonist the affinity of the G protein to GTP is increased. [35S]GTPγS 
replaces endogenous GTP and binds to the Gα subunit. [35S]GTPγS is resistant 
against hydrolysis by the intrinsic GTPase activity of Gα. Therefore bound 
[35S]GTPγS to Gα can be measured. Conclusions concerning the pharmacological 
behavior of the tested ligand and calculation of its potency and efficacy can be drawn 
by quantifying the change of bound [35S]GTPγS in relation to basal. Measurements of 
receptor-mediated G protein activation via [35S]GTPγS binding assays are sensitive 
test systems and offer the possibility to evaluate pharmacological parameters of a 
ligand at a very proximal point of the signal cascade, which minimizes interfering 
factors (Seifert and Wieland, 2005).  
Due to the ability of CBRs to modulate cAMP production, adenylyl cyclase 
assays are often exploited to screen potential CBR ligands. Furthermore, Rhee et al. 
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(1998) could show, that regulation of adenylyl cyclase isoforms 1, 3, 5, 6 or 8 by 
CB1R activation resulted in an inhibition of cAMP accumulation, whereas for isoforms 
2, 4, or 7 a stimulation of cAMP accumulation was computed (Rhee et al., 1998). 
This supported the assumption that CB1R can also couple to Gαs proteins (Glass and 
Felder, 1997). 
CB1Rs are located on presynaptic terminals and mediate inhibition of electrically 
evoked transmitter release. These transmitters cause muscle contraction, which can 
be measured in in-vitro assays using isolated vas afferens from mice or small 
intestine muscle preparation of guinea pig. Of course, several other signal pathways 
can alter the contraction of these muscles and thus it is necessary to proof selective 
CBR dependency with a selective CB1R antagonism. 
1.2.4 The ECS as therapeutic target 
The ECS is involved in many physiological functions. Investigations for targeting 
this system in pathophysiological conditions are up-coming since it has been realized 
that Marijuana and its active secondary metabolites has - beneath its risk of abuse 
and addiction - a huge clinical potential. The involvement of the ECS in energy 
metabolism and appetite regulation is proven and modulation of CBR activity can be 
effectively used for the treatment of metabolic diseases like obesity and anorexia. 
Targeting increased activity of the EC system in obese animals led to the 
development of the CB1R inverse agonist rimonabant, which caused significant 
weight loss with beneficial effects on different metabolic parameters (Patel and 
Pathak, 2007). While in obese or overweight patients weight loss is a main goal, 
diminished appetite is an immense problem for HIV, Alzheimer or cancer patients. It 
was demonstrated that cannabis not only increased appetite, but was also effective 
in improving the mood and decreasing (chemotherapy-related) nausea and emesis 
(Nauck and Klaschik, 2004). 
Also, the ECS figures prominently in the CNS and is associated to disorders 
and diseases. This is not surprising since the CB1R is the most abundant GPCR in 
the brain with particularly high densities in the cerebral cortex, cerebellum, 
hippocampus and basal ganglia (Herkenham et al., 1991). These areas are related to 
motor, mood and anxiety disorders, as well as to the brain rewarding system and 
processes of learning and memory. Therefore, targeting the CB1R for therapeutically 
purposes in pathophysiological conditions as Parkinson´s disease, Huntington´s 
disease, amyotrophic lateral sclerosis, epilepsy and Gilles de la Tourette´s syndrome 
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is under investigation. Other mental CNS disorders as depression, anxiety and 
insomnia seem to be sensitively modulated by the ECS and pharmacological 
interventions are studied. Also for the treatment of Alzheimer´s disease, beneficial 
effects of cannabinoids are discussed. For example, it was demonstrated that ∆9-
THC inhibits acetyl cholinesterase and prevents amyloid β-peptide aggregation 
(Eubanks et al., 2006).  
Sativex®, a ∆9-THC/Cannabidinol standardized Cannabis sativa extract, is 
approved as adjunctive medication for patients with multiple sclerosis (MS) in 
Canada since 2005 (Barnes, 2006). MS is a complex, auto-immune, inflammatory 
disease which leads into demyelination and axonal damage. The add-on therapy with 
Sativex® relieved neuropathic pain, lowered spasm frequency and increased mobility 
in MS patients, not responding to other drugs. In July 2010, approval has given to 
Sativex® in Spain and the drug manufacturer GW pharmaceuticals already submitted 
the application for approval in other European countries. 
Another topic of investigation is the involvement of the ECS in inflammatory and 
neuropathic pain conditions. The precise mechanisms underlying nociception are not 
jet fully understood. Beside (endo-)cannabinoid induced modulation of inflammatory 
regulation (Pandey et al., 2009) and suppression of cellular nociceptive responses 
(Walker and Huang, 2002), an interplay of the ECS and the opioid system is 
discussed (Parolaro et al., 2010). Animal pain models offer promising results of 
cannabinoids blocking pain responses (Walker and Huang, 2002). Studies with 
knock-out mice showed that both CBRs are involved in the modulation of 
antinociception (Fox and Bevan, 2005) and that the peripheral CB1Rs play a greater 
role than those localized in the CNS (Agarwal et al., 2007). In humans, beneficial 
effects of cannabis or synthetic cannabinoids in pain associated with MS, cancer, 
neuropathies and HIV infections are reported, but because of central side effects the 
widespread application is limited. Nevertheless, the antinociceptive effects, the 
interaction with the opioid system and the action mediated via peripheral CBRs 
provide a complex, but solid base for the development for cannabinoids that do not 
cross the brain-blood barrier. This would result in a novel class of analgetics 
peripherally acting against inflammatory or neuropathic pain. 
As mentioned above, cannabinoids exhibited palliative effects in cancer 
patients. This includes appetite stimulation, inhibition of nausea and emesis during 
chemotherapy, pain relief and mood elevation. Furthermore, studies showed that 
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they might direct inhibit cancer growth through complex mechanisms that may 
involve apoptosis induction and anti-proliferative, anti-angiogenic and anti-metastatic 
effects in various cancer types (Bifulco et al., 2007). For example, CB2R selective 
agonist JHW-133 inhibited tumor angiogenesis through reduction of vascular 
endothelial cell migration and inhibition of tumor expressed pro-angiogenic factors, 
such as vascular endothelial growth factor (VEGF), matrix-metalloproteinase-2 and 
angiopoietin (Blazquez et al., 2003). Blocking pro-angiogenic factors with a remedy 
that has “side benefits” may provide an interesting therapeutic approach for cancer 
therapy. 
Other promising clinical approaches are targeting the ECS for Asthma therapy - 
because of the well known anti-inflammatory effects of cannabinoids and reports that 
endogenous cannabinoids can modulate bronchodilatation (Calignano et al., 2000) -, 
for the treatment of glaucoma - where some cannabinoids could effectively lower 
intraocular pressure, which was mainly CB1R dependent (Porcella et al., 1998) - and 
for prevention of osteoporosis (Bab and Zimmer, 2008). 
The ECS is a very complex and fine-tuned system and further studies and 
investigations are required to fully understand the physiological and 
pathophysiological role and possibilities of intervention. Of course, the negative side 
effects of cannabis such as the enhanced incidence of amotivational syndrome 
(Tunving, 1987) and increased risk of schizophrenia-like psychoses (Murray et al., 
2007) must be monitored carefully or can, in a best-case scenario, be avoided by 
highly selective compounds or more selective distribution patterns. However, the 
above mentioned diseases, that are by no means complete, are being treated or 
have the potential to be treated by modulating ECS activity. 
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1.3 Objectives 
Since the discovery of the ECS its involvement in many physiological functions 
and therapeutic interventions in pathophysiological conditions are investigated. As 
well as targeting biosynthesis and degradation of endocannabinoids for modulation of 
ECS signaling, the two so far known CBRs provide promising drug targets. Hence, 
new and preferable selective CBRs agonists, inverse agonists and antagonists are 
desired and test systems for ligand screening procedures are needed. 
The aim of this thesis was to establish a functional and efficient assay system 
for the search and characterization of new CBR ligands. Therefore, different cell or 
tissue membranes heterogeneously or endogenously expressing CBR should be 
investigated on their ability to serve as an appropriate expression system. Finally, the 
steady-state GTPase assay should be developed and validated with known standard 
ligands in the most suitable expression system to characterize the pharmacological 
property of CBR ligands at a very proximal point of the signal transduction cascade. 
To examine whether the sensitivity of the test system can be enhanced, the influence 
of different co-expressed RGS proteins should be explored. 
The second part of the thesis focused on the investigation and characterization 
of CBR-Gα fusion proteins. Fusion of the receptor to Gαi2 subunit should be 
constructed and studies on their impact on receptor pharmacology was to be 
conducted. In addition, our interest was again to explore how RGS proteins would 
influence G protein signaling in the fusion approach and how this interaction is 
altered compared to the system where the CBRs are co-expressed with Gαi2. 
Finally, the assay with the highest sensitivity should be applied to examine 
potential ligands concerning their CBR activity. These ligands include natural 
compounds isolated from different Echinacea species as well as synthetic 2,3-
disubstituted indole derivatives. 
In summary, this thesis comprises the establishment of a highly sensitive assay 
system that is suitable for analyzing CBR pharmacology and for ligand screening 
procedures.  
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2 Establishment of recombinant cannabinoid receptor assays and 
characterization of several natural and synthetic ligands* 
2.1 Abstract 
Cannabinoid receptors (CBR) are important drug targets for the treatment of 
various inflammatory, metabolic and neurological diseases. Therefore, sensitive test 
systems for the assessment of ligands are needed. In this study, a steady-state 
GTPase assay for human CBR subtypes 1 and 2 was developed to characterize the 
pharmacological property of ligands at a very proximal point of the signal 
transduction cascade. Establishing these in-vitro test systems, we studied cell or 
tissue membranes heterogeneously or endogenously expressing CBR, such as CBR 
infected Human Embryonic Kidney (HEK) 293 cells, rat cerebellum and spleen cells. 
The lack of effects in the GTPase assay and in [35S]GTPγS binding experiments in 
these expression system, directed us to use Spodoptera frugiperda (Sf9) cells. Co-
expressing CBR, different Gα subunits, Gβγ heterodimer and RGS (Regulator of G 
protein signaling) proteins in Sf9 cell membranes greatly improved the sensitivity of 
the assay, with highest GTPase activation in the CBR + Gαi2 + Gβ1γ2 + RGS4 
system. We examined exogenous and endogenous standard ligands as well as 
secondary metabolites as ∆9-tetrahydrocannabinol (∆9-THC), dodeca-2E,4E-dienoic 
acid isobutylamide, an alkamide from Echinacea purpurea, and an Echinacea 
purpurea hexane extract according their agonistic and antagonistic properties. The 
suitability of the assay for screening procedures was also proven by detecting the 
activity of ∆9-THC in a matrix of other less active compounds (∆9-THC free Cannabis 
sativa extract). In conclusion, we have developed highly sensitive test systems for 
the analysis of CBR ligands. 
                                            
* This chapter is adapted from: Geiger S, Nickl K, Schneider EH, Seifert R and Heilmann J (2010) 
Establishment of recombinant cannabinoid receptor assays and characterization of several natural 
and synthetic ligands. Naunyn Schmiedebergs Arch Pharmacol 382:177-91 
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2.2 Introduction  
Cannabinoid receptors (CBRs) and their ligands have been of interest since 
their discovery in the early 1990’s. The first CBR mainly expressed in the CNS was 
cloned in 1990 and named CB1R (Howlett et al., 2002). A second cannabinoid 
receptor (CB2R), mainly found in the periphery on immune cells and tissues, was 
discovered in 1993 (Howlett et al., 2002).  
Ligands of cannabinoid receptors are of high therapeutic interest since the 
endocannabinoid system (ECS) is involved in the regulation of several biological 
functions such as immune regulation, memory, movement, appetite and pain (De 
Petrocellis et al., 2004; Di Marzo et al., 2004). Targeting increased activity of the 
ECS in obese animals led to the development of the first CB1R antagonist/inverse 
agonist named rimonabant. Currently, the interrelationship between 
neuroinflammatory disorders such as Alzheimer’s disease, amyotrophic lateral 
sclerosis, multiple sclerosis and Parkinson`s disease with malfunctions of the CBR 
system is under investigation (Centonze et al., 2007). Activation of CB1R by agonists 
results in anticonvulsive and neuroprotective effects during ischemia and after 
traumatic brain injury (Panikashvili et al., 2001; Marsicano et al., 2003). Furthermore, 
the connection of the ECS and pain is still a topic of intensive investigation (Lever 
and Rice, 2007). 
A major problem in the search for new CBR ligands is the limited number of 
available in-vitro test systems for their functional characterization and mechanistic 
studies, whereas several well established models for the in-vivo effects of CBR 
ligands exist (Cheng and Hitchcock, 2007). Often, competition binding assays with 
radioligands are applied (McPartland et al., 2007). However, these assays do not 
allow the differentiation of full or partial agonists, inverse agonists and antagonists. 
Available functional test systems measure the effects at a rather distal point of the 
signal cascade via second messengers, e. g. the increase of intracellular Ca2+ levels 
or the measurement of cAMP concentrations (Navarro et al., 2009; Silvestri et al., 
2008). These second messengers are sometimes influenced by receptor-
independent effects or cross-talk from other targets addressed by the test compound. 
Further information can be obtained by GTPγS binding assays kinetically determining 
the GDP/GTP exchange at the Gα subunit using [35S]GTPγS, an assay that was 
recently successfully established in Sf9 cell membranes (Nickl et al., 2008). 
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The aim of our present study was to establish a highly sensitive functional CBR 
assay to study CBRs and their ligands at a proximal point of the signal cascade. A 
guide for the establishment of such systems is provided by the corresponding models 
established for the β2 adrenergic receptor (Seifert et al., 1999a) and the formyl 
peptide receptor (Wenzel-Seifert et al., 1999). Activation of a receptor initiates its 
binding to the Gα subunit accompanied with the exchange of bound GDP to GTP 
resulting in the dissociation of the ternary Gα-GTP-Gβγ complex into the subunits 
Gα-GTP and Gβγ. Deactivation of the G protein is accomplished by the intrinsic 
GTPase activity of the Gα subunit hydrolyzing GTP to GDP and Pi (Seifert and 
Wenzel-Seifert, 2002). Using [γ-32P]GTP, the amount of 32Pi released by the intrinsic 
GTPase activity of Gα under state conditions can be measured. 
We adopted this concept and established CB1R and CB2R steady-state GTPase 
assays. As expression systems, we used membranes of rat cerebellum and spleen, 
endogenously expressing CBRs, as well as membranes of CBR transfected HEK 293 
cells and Sf9 cells, co-expressing CBR, different Gα subunits, Gβγ heterodimer and 
various RGS proteins. For validation several exogenous and endogenous ligands of 
CBRs, i.e. anandamide, 2-AG (2-arachidonoyl glycerol), CP 55,940 ((-)-cis-3-[2-
hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol), WIN 
55,212-2 ((R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-
benzoxazin-6-yl]-1 naphthalenylmethanone mesylate) as well as AM 251 (N-
(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-
carboxamide), AM 281 (1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-
morpholinyl-1H-pyrazole-3-carboxamide) and AM 630 (6-iodo-2-methyl-1-[2-
4(morpholinyl)-ethyl]-[1H-indol-3-yl]-(4-methoxyphenyl)methanone) (Figure 2.1) were 
characterized. 
Since the discovery of ∆9-THC (Figure 2.1), isolated from Cannabis sativa L. 
var. indica (Cannabaceae) as an agonist on CBRs, secondary natural products have 
also been addressed as promising leads for the discovery of cannabinoid ligands. 
Recently, other natural products like the alkamides from Echinacea species (Raduner 
et al., 2006) and β-caryophyllene (Gertsch et al., 2008) have been addressed as 
ligands of the CB2R and thus, one of the main alkamides from Echinacea purpurea, 
dodeca-2E,4E-dienoic acid isobutylamide, was tested in our assay (Figure 2.1).  
Due to the fact that secondary natural metabolites almost exclusively occur as 
mixtures, a screening test system applicable for bioactivity guided isolation of natural 
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compounds must be sensitive enough to detect single active compounds in a matrix 
of other inactive compounds. Therefore, we evaluated the potential of our assay to 
detect ∆9-THC artificially added to a ∆9-THC free cannabis extract and tested an 
alkamide containing Echinacea purpurea root extract.  
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Figure 2.1: Structures of the investigated compounds  
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2.3 Materials and Methods 
2.3.1 Materials 
The cDNA for hCB1R and hCB2R in pcDNA 3.1 was obtained from the cDNA 
bank of the University of Missouri (Rolla, MO, USA). All restriction enzymes and T4 
ligase were from New England Biolabs (Beverley, MA, USA). Cloned Pfu DNA 
polymerase was from Stratagene (La Jolla, CA, USA). PCR primers were 
synthesized by MWG Biotech (Ebersberg, Germany), dNTP mix was obtained from 
Promega (Madison, WI, USA). pcDNA3.1(+) plasmid was purchased by Invitrogen 
(Carlsbad, CA, USA). Baculovirus encoding for Gα0 was a kind gift of Dr. J. Garrison 
(University of North Carolina, Chapell Hill, NC, USA). Baculovirus encoding Gαi2 was 
generously provided by Dr. A. G. Gilman (Department of Pharmacology, University of 
Texas, Southwestern Medical Center, Dallas, TX, USA). Baculovirus encoding Gβ1γ2 
was a kind gift from Dr. P. Gierschik (Department of Pharmacology, University of 
Ulm, Germany). Baculoviruses encoding for RGS4 and RGS19 were a kind gift from 
Dr. E. Ross (University of Texas, Southwestern Medical Center, Dallas, TX, USA). 
Phenylmethylsulfonylfluoride and leupeptine hemisulfate were from Calbiochem (La 
Jolla, CA, USA). Benzamidine was from Sigma (99%, St. Louis, MO, USA). Adenylyl 
imidodiphosphate was obtained from Roche (Mannheim, Germany). [35S]GTPγS 
(1,100 Ci/mmol) was purchased from PerkinElmer (Boston, MA, USA), [γ-32P]GTP 
was synthesized through enzymatic phosphorylation of GDP and 
[32P]orthophosphoric acid (8,000 Ci/mmol, PerkinElmer Life Sciences, Boston, MA, 
USA) as described previously (Walseth and Johnson, 1979).  
All nucleotides, unlabeled GTPγS, creatine kinase, creatine phosphate and salts 
(highest purity available) were purchased either from Roche (Mannheim, Germany) 
or Sigma (St. Louis, MO, USA). Dimethyl sulfoxide was from Merck (Darmstadt, 
Germany). Tris base was purchased from USB (Cleveland, OH, USA).  
GF/C filters were from Brandel (Gaithersburg, MD, USA) and Rotiszint® eco 
plus cocktail was from Roth Chemie (Karlsruhe, Germany). Radioactive samples 
were counted in a PerkinElmer Tricarb-TR liquid scintillation analyzer.  
The CBR ligands CP 55,940, anandamide, 2-AG, WIN 55,212-2, AM 251 and 
AM 630 were purchased from Tocris Cookson (Ballwin, MO, USA).  
∆9-THC was obtained by THC Pharm (Frankfurt/Main, Germany). Dodeca-
2E,4E-dienoic acid isobutylamide (2 mM (w/v) in DMSO) was a kind gift of Dr. J. 
Gertsch (ETH Zurich, Switzerland). An ethanolic ∆9-THC free Cannabis sativa extract 
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was obtained from the Bundesinstitut für Arzneimittel und Medizinprodukte (Bonn, 
Germany). The Echinacea hexane extract was prepared from the roots of Echinacea 
purpurea (kind gift of Martin Bauer GmbH, Alveslohe, Germany) through Accelerated 
Solvent Extraction (ASE 100, Dionex, Germering, Germany). 
 
2.3.2 Methods 
2.3.2.1 Construction of FLAG epitope- and hexahistidine-tagged hCBR and 
pcDNA3.1-hCBR plasmids 
hCBR constructs were generated according to a previously described strategy 
using sequential overlap-extension polymerase chain reaction (PCR) (Nickl et al., 
2008; Wenzel-Seifert et al., 1999; Wenzel-Seifert and Seifert., 2000). Briefly, a DNA 
sequence encoding the cleavable signal peptide from influenza hemagglutinin to 
direct the receptor protein to the cell membrane, followed by the FLAG epitope, 
which is recognized by the respective monoclonal antibody, was placed 5’ of the start 
codon of the cDNA of the CBRs; 3’ of the cDNA a hexahistidine (His6) was placed to 
allow further purification. These DNA constructs were used for generation of 
recombinant baculoviruses and were also inserted between the KpnI and XbaI sites 
(CB1R) and the KpnI and XhoI sites (CB2R), respectively, of the pcDNA3.1(+) 
plasmid. Constructs were confirmed by extensive restriction enzyme analysis and 
enzymatic sequencing. 
2.3.2.2 Cell culture, transfection, membrane preparation and cell microscopy of 
HEK 293 cells 
HEK 293 cells were cultivated in Dulbecco´s modified eagle medium 
supplemented with 10% (v/v) bovine serum albumin BSA (Invitrogen, Carlsbad, CA, 
USA). Cells were transfected in 24 well plates with 0.5 µg of pcDNA-CBR plasmid 
DNA using Fugene HD transfection reagent (Roche, Mannheim, Germany).  
For membrane preparation, cells were seeded in culture flasks and incubated 
until a density of approximately 95%. Cells were scraped off the plates and 
membranes were prepared by analogy to the procedure described for Sf9 membrane 
preparation. 
For imaging, cells were seeded in BD Biosciences 8 well chamber slides (San 
Jose, CA, USA) at a density of 70-80% and incubated overnight. Cells were fixed for 
30 min with 4% (w/v) paraformaldehyde (Sigma, St. Louis, MO, USA), permeabilized 
with 0.2% (w/v) Triton X-100 (Serva, Heidelberg, Germany), washed and incubated 
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for 1 hour with anti-FLAG polyclonal (rabbit) antibody (Sigma, St. Louis, MO, USA), 
1:400 (v/v) diluted in PBS buffer containing 0.5% BSA. After washing, cells were 
incubated with Cy2-conjugated AffiniPure Goat Anti-Rabbit IgG (Dianova, Hamburg, 
Germany) 1:400 (v/v) diluted in PBS buffer containing 0.5% BSA, for 1 hour. 
Thereafter, preparation was mounted with Confocal Matrix (Micro Tech Lab, Graz, 
Austria) and hardened overnight. A Carl Zeiss Axio Observer Z1 microscope was 
employed for acquisition of fluorescence images. 
2.3.2.3 Animals and rat cerebellum membrane preparation 
The study was conducted in accordance with the European Communities 
Council Directive (86/609/EEC) and of the Local Government of the Oberpfalz 
(Bavaria, Germany). All efforts were made to minimize the number of rats used and 
their suffering. Male rats (12 weeks of age, 430 - 560 g body weight; Charles River, 
Sulzfeld, Germany) was kept in the animal facilities under standard laboratory 
conditions (12:12 light-dark cycle, lights on at 6 a.m., 22°C, 55% relative humidity) 
with free access to water and standard rat chow. The rat was killed with an 
increasing concentration of CO2. The cerebellum and the spleen were removed, 
quickly frozen in prechilled n-methyl butane on dry ice, and stored at -20°C unti l 
further processing. For membrane preparation, tissues was homogenized in 10 mM 
Tris/HCl buffer, pH 7.4, containing 1 mM EDTA, 0.2 mM phenylmethyl-
sulfonylfluoride, 10 µg/ml benzamidine, 10 µg/ml leupeptin with an Ultra-Turrax 18-10 
(IKA, Staufen, Germany). After centrifugation at 500 x g for 15 min, the supernatant 
fluid was decanted and the membrane pellet was obtained by spinning the 
supernatant at 20,000 x g for 30 min. The pellet was washed and homogenized in 
buffer containing 75 mM Tris/HCl, pH 7.4, 1 mM EDTA and 12.5 mM MgCl2. Aliquots 
were stored at -80°C. Protein concentration was det ermined using the DC protein 
assay kit (Bio-Rad, Hercules, CA) according to the instructions of the manufacturer. 
2.3.2.4 Generation of recombinant baculoviruses and membrane preparation of 
transfected Sf9 cells 
Sf9 cells, derived from Spodoptera frugiperda pupal ovarian tissue, were used 
for the baculovirus expression. Sf9 cells were cultured in Erlenmeyer flasks at 28°C 
under rotation at 125 rpm in SF 900 II medium (Invitrogen, Carlsbad, CA, USA), 
supplemented with fetal calf serum (Pan-Biotech, Aidenbach, Germany) to 5% (v/v) 
and gentamicin sulfate (BioWhittaker, Walkersville, MD, USA) to 0.1 mg/ml. 
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Recombinant baculoviruses encoding FLAG- and hexahistidine-tagged CB1R and 
CB2R, Gβ1γ2 as well as varying Gα subunits (Gα0, Gαi2) and RGS proteins (RGS4 
and RGS19) were generated in Sf9 insect cells using the BaculoGOLD transfection 
kit (BD PharMingen, San Diego, CA) (Seifert and Wenzel-Seifert 2001; Wenzel-
Seifert et al., 1999; Wenzel-Seifert and Seifert, 2000) according to the 
manufacturer´s instructions. After initial transfection, high-titer virus stocks were 
generated by two sequential virus amplifications. 
For transfection, cells were seeded (cell density 3.0 x 106 cells/ml) and infected 
with a 1:100 dilution of high-titer baculovirus stocks. Cells were cultured for 48 h and 
Sf9 membranes were prepared as described previously (Wenzel-Seifert and Seifert, 
2000). Briefly, cells were washed once by centrifugating for 10 min at 170 x g, 
discarding the supernatant and resuspending the cell pellet in PBS buffer. After 
repeating the centrifugation step, the supernatant fluid was discarded and the pellet 
was suspended in lysis buffer (containing 10 mM Tris/HCl pH 7.4, 1 mM EDTA, 
0.2 mM phenylmethylsulfonylfluoride, 10 µg/ml benzamidine, 10 µg/ml leupeptin) and 
homogenized in a Dounce homogenizer with 25 strokes. After centrifugation at 40 x g 
for 5 min the pellet contained the nuclei and unbroken cells and the supernatant 
contained the membranes. Therefore, the supernatant fluid was carefully transferred 
to a plastic tube and spun down by 38,500 x g for 20 min. The pellet containing the 
membranes was resuspended in lysis buffer and again centrifuged as described 
above. The resultant membrane pellet was suspended in buffer containing 75 mM 
Tris/HCl, pH 7.4, 1 mM EDTA and 12.5 mM MgCl2, homogenized by a syringe with 
20 strokes and stored in aliquots at -80°C. Protein  concentrations were determined 
using the DC protein assay kit (Bio-Rad, Hercules, CA) according to the instructions 
of the manufacturer. Membranes used in the assays were analyzed by SDS page 
and immunoblotting with specific antibodies against FLAG-tagged cannabinoid 
receptors, G protein subunits and RGS proteins to ensure correct transfection (Nickl 
et al., 2008). 
2.3.2.5 Solubility of CBR ligands 
All compounds were dissolved in DMSO 100% (v/v) or in BSA (1 mg/ml) and 
stored at -20° C. The final DMSO concentration in a ssays in all cases was 3% (v/v) 
and did not influence the functionality of the assay (Table 2.3). 
Chapter 2: Establishment of recombinant CBR assays 
 
- 37 - 
 
2.3.2.6 [35S]GTPγS binding experiments 
 To determine the agonist-stimulated guanine nucleotide binding to G proteins, 
[35S]GTPγS binding experiments were performed in the presence of GDP at 
increasing concentrations according to a previously described protocol (Seifert et al., 
1998). Briefly, membranes were thawed, sedimented by centrifugation at 18,000 x g 
for 10 min at 4°C, and carefully homogenized in bin ding buffer containing 75 mM 
Tris/HCl, pH 7.4, 1 mM EDTA and 12.5 mM MgCl2. Assay tubes contained 0.25% 
(w/v) BSA, membranes of rat cerebellum (2.5 µg of protein) or rat spleen (5 µg of 
protein), 0.4 nM [35S]GTPγS and varying concentrations of GDP ranging from 1 nM to 
10 µM for rat cerebellum and 10 nM to 100 µM for rat spleen in 250 µl binding buffer. 
Binding of [35S]GTPγS was examined in the absence and presence of 10 µM 
CP 55,940 with or without 100 mM NaCl. Non-specific binding was determined in the 
presence of 100 µM unlabeled GTPγS and was less than 0.4% of total binding. 
Incubation was conducted for 90 min at room temperature and shaking at 250 rpm on 
a platform shaker (InnovaTM 2000, New Brunswick Scientific, Edison, NJ, USA). 
Assays were stopped by filtration through GF/C filters equilibrated with binding buffer. 
After filtration, filters were washed 3 times with cold binding buffer (4°C) and filter-
bound radioactivity was determined by liquid scintillation counting in Rotiszint® eco 
plus cocktail after 4 hours of equilibration. 
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2.3.2.7 Steady-state GTPase assay 
The GTPase assay was performed as described previously (Wenzel-Seifert et 
al., 1999). Briefly, membranes were thawed, sedimented by centrifugation at 
18,000 x g for 10 min at 4°C, and carefully resuspe nded in 10 mM Tris/HCl, pH 7.4. 
Assay tubes contained membranes (HEK 15 µg, rat cerebellum 2.5 µg, rat spleen 5 
µg, Sf9 15 µg of protein/tube), 1.0 mM MgCl2, 0.1 mM EDTA, 0.1 mM ATP, 100 nM 
GTP, 0.1 mM adenylyl imidodiphosphate, 5 mM creatine phosphate, 40 µg of 
creatine kinase, 0.2% (w/v) BSA in 50 mM Tris/HCl, pH 7.4, to prevent binding of 
protein or ligand to the polystyrol tubes, and CB1R and CB2R ligands at various 
concentrations. To suppress constitutive activity of CB1Rs in rat cerebellum, 150 mM 
NaCl was added to assay tubes (Wenzel-Seifert et al., 1998). This addition enabled 
us to increase the effect of an agonist on GTPase activity. Reaction mixtures (80 µl) 
were incubated for 2 min at 25°C before the additio n of 20 µl of [γ-32P]GTP 
(0.1 µCi/tube). All stock and work dilutions of [γ-32P]GTP were prepared in 20 mM 
Tris/HCl, pH 7.4. Reactions were conducted for 20 min and 10 min for rat tissues, 
respectively, at 25°C. Reactions were terminated by  the addition of 900 µl of slurry 
consisting of 5% (w/v) activated charcoal and 50 mM NaH2PO4, pH 2.0. Charcoal 
absorbs nucleotides but not 32Pi. Charcoal-quenched reaction mixtures were 
centrifuged for 7 min at room temperature at 15,000 x g. Six hundred µl supernatant 
fluid of reaction mixtures was removed and 32Pi was determined by Čerenkov 
radiation in 3 ml water. Enzyme activities were corrected for spontaneous 
degradation of [γ-32P]GTP. Spontaneous [γ-32P]GTP degradation was determined in 
tubes containing all of the above described components plus a high concentration of 
unlabeled GTP (1 mM) that, by competition with [γ-32P]GTP, prevents [γ-32P]GTP 
hydrolysis by enzymatic activities present in Sf9 membranes. Spontaneous  
[γ-32P]GTP degradation amounted to <1% of the total amount of radioactivity added. 
The experimental conditions chosen ensured that not more than 20% of the total 
amount of [γ-32P]GTP added was converted to 32Pi. Neutral antagonism was 
determined in the presence of 30 nM (Table 2.4) or 10 nM CP 55,940 (Figure 2.6).  
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2.3.2.8 Calculations and statistics 
Data are expressed as means ± SD and represent a minimum of 3 independent 
experiments, each performed in triplicate. Statistical evaluations and curve fittings 
were calculated using the GraphPad Prism 4 software (La Jolla, CA) and the 
Microsoft Excel 2007 software. Kb values were derived from the equation by Cheng 
and Prusoff (Cheng and Prusoff, 1973). 
 To compare more than two values, statistical significance was determined by 
the one-way ANOVA (Table 2.2), followed by the Dunnett post test. The statistical 
evaluation of two values was performed with the Student´s t-test. P values are given 
in the text (section results) and in the respective tables. 
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2.4 Results 
2.4.1 CBR transfected HEK 293 cells 
 To obtain a mammalian test system, CBRs were expressed in HEK 293 cells. 
Expression of receptor proteins was confirmed with immunostaining (Figure 2.2). 
Both receptors were present at the plasma membrane, and in CB1R transfected HEK 
293 cells a fraction of the receptor was additionally localized in intracellular vesicles.  
Although the CBR were clearly expressed, the use of HEK 293 cell membranes 
did not allow us to successfully establish the steady-state GTPase assay in 
mammalian cells. Despite intense efforts, with different CBR ligands no change of 
GTPase activity was observed (data not shown). 
 
    
 
Figure 2.2: Immunostaining of CBR transfected HEK 293 cells 
Cell staining was performed as described in Material and Methods. CB1R transfected HEK 293 cells 
show localization of receptor at the plasma membrane and in intracellular vesicles (A), whereas in 
CB2R-transfected HEK 293 cells the receptor is predominantly localized at the plasma membrane (B).  
 
2.4.2 GTPγS binding experiments in rat cerebellum and rat spleen membrane 
To determine the effect of agonists on guanine nucleotide exchange, 
[35S]GTPγS bindings were conducted, in the presence of GDP at increasing 
concentrations (Figure 2.3). In rat cerebellum membranes, GDP inhibited [35S]GTPγS 
binding with a logIC50 value of -7.16 ± 0.10. In the presence of an agonist the affinity 
of Gα for GDP should be decreased (Seifert et al., 1998) resulting in a right-shift of 
the concentration-response curve. However, the addition of 10 µM CP 55,940 did not 
significantly change the affinity of the G proteins for GDP (logIC50 value of -7.20 ± 
0.09). Even the addition of 100 mM NaCl did not unmask a measurable right-shift 
(logIC50 value of -7.18 ± 0.06 and -7.21 ± 0.07 in the presence of agonist CP 55,940). 
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In contrast, in myeloid differentiated HL-60 membranes, NaCl was very effective at 
enhancing agonist effects on [35S]GTPγS binding (Gierschik et al., 1991). 
Analysis of rat spleen membranes revealed a similar pattern. In this system, a 
logIC50 value of -6.90 ± 0.08 for the GDP competition under basal conditions was 
determined. In the presence of CP 55,940, a logIC50 value of -6.86 ± 0.09 for GDP 
was measured. Again, NaCl did not influence the sensitivity of the system (logIC50 
value of -7.16 ± 0.07 for GDP and -7.14 ± 0.08 in the presence of agonist CP 
55,940).  
 
Figure 2.3: Effect of CP 55,940 on GTPγS binding in rat cerebellum and spleen membrane 
GDP affinity binding was determined as described in Materials and Methods. Data show the merged 
results of 3 independent [35S]GTPγS binding assays. Reaction mixtures contained 0.4 nM [35S]GTPγS 
and GDP at the concentrations indicated on the abscissa in the absence (A and B) or presence 
(C and D) of 100 mM NaCl. Data were obtained for rat cerebellum membrane (A and C) and rat 
spleen membrane (B and D) with (○) and without (●) 10 µM CP 55,940. 
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2.4.3 Analysis of GTPase activity in rat tissue membrane 
 Rat cerebellum membranes exhibited a substantial basal GTPase activity 
(Table 2.1). The addition of 150 mM NaCl to the reaction mixture resulted in a 
decreased constitutive activity of the CB1R in rat cerebellum membrane, resulting in 
an increased agonist effect (Table 2.1). In this system we could reach 15 ± 2% 
stimulation above basal by CP 55,940. A reduction of 19 ± 2% from basal GTPase 
activity was achieved with AM 251 in absence of NaCl. However, for detailed 
pharmacological studies, these signals were far too small. 
 In rat spleen membrane no change of GTPase activity was measurable with 
agonist CP 55,940 in concentrations from 1 nM to 10 µM. Also, the CB2R antagonist 
AM 630 did not show any effect in the concentrations from 1 nM to 100 µM, whether 
in the normal or in the antagonist mode (data not shown). 
 
 
Table 2.1: Analysis of GTPase activity of CB1R in rat cerebellum membrane 
 
Basal activity Activity with 10 uM ligand 
[pmol x mg-1 
 x min-1] 
[pmol x mg-1  
x min-1] 
[% change of 
basal activity] 
CP 55,940 25.05 ± 2.41 27.18 ± 2.24 9 ± 4 
CP 55,940 with 150 mM NaCl 15.57 ± 0.77 17.88 ± 1.08 15 ± 2 
AM 251 25.00 ± 2.60 20.22 ± 1.96 -19 ± 2 
 
GTPase activity was determined as described in Materials and Methods. Reaction mixture contained 
CP 55,940 and AM 251 at concentrations from 1 nM to 10 µM to generate sigmoidal concentration-
response curves. Data were analyzed by nonlinear regression and best fit to sigmoidal concentration-
response curves. Data shown are the mean values ± SD and represent 4 independent experiments 
performed in triplicates. 
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2.4.4 Analysis of six different co-expression systems of CBRs in Sf9 cells 
To obtain a highly sensitive test system for the CBRs we compared the co-
expression of Gα0 and Gαi2 subunits in Sf9 insect cells. Gα0 is expressed in neuronal 
and
 
neuroendocrine cells, whereas
 
Gαi2 is ubiquitously expressed (Offermanns, 
2003). Furthermore, we evaluated the potential effects of GTPase activating proteins 
(GAPs) (Ross and Wilkie, 2000) on the GTPase activity and started our 
investigations with RGS4 and RGS19, using in all constructs the additional 
heterodimer Gβ1γ2. In previous studies on the human histamine H4 receptor and 
chemokine receptor CXCR4, RGS proteins enhanced agonist-stimulated GTP 
hydrolysis (Schneider and Seifert, 2009; Kleemann et al., 2008). 
Expression of the Gα0 subunit resulted in a low GTPase activation by 10 µM 
CP 55,940 (19 ± 9% for CB1R and 27 ± 6% for CB2R, Table 2.2). In contrast, the 
expression of Gαi2 increased the GTPase stimulation to 53 ± 19% for CB1R and 70 ± 
13% for CB2R, Table 2.2). The co-expressed RGS protein significantly influenced the 
GTPase activation. Co-expression with RGS4 was beneficial for all used constructs, 
with the highest increase in membranes with Gαi2 and RGS4 (CB1R: 158 ± 8% 
stimulation and CB2R: 156 ± 15%, Table 2.2), whereas RGS19 co-expression was 
only beneficial for the CB1R + Gα0 construct. LogEC50 values were not statistically 
different for the CB1R in all constructs (p = 0.9181), but the increase of GTPase 
stimulation of CB1R + Gαi2 + Gβ1γ2 + RGS4 was significantly higher with a p value of 
< 0.001 compared to all other CB1R constructs. Also, the p value for the comparison 
of GTPase stimulation of CB2R + Gαi2 + Gβ1γ2 + RGS4 construct to the other CB2R 
constructs is ≤ 0.001, showing a very high significant difference. Interestingly, the 
logEC50 of CP 55,940 on the CB2R + Gα0 construct is significantly different from all 
other constructs with a p value of 0.0136. Regarding the baseline values of the 
different constructs, the CB1R + Gαi2 system with RGS4 and RGS19 showed a 
significant increase of basal activity (p = 0.0034), whereas in the CB2R + Gαi2 system 
only RGS4 influenced basal activity positively (p < 0.001). 
Based on these results we went on working with the CBR + Gαi2 + Gβ1γ2 + 
RGS4 construct for further experiments. This system showed the highest sensitivity 
recognizable at the highest GTPase stimulation by CP 55,940 with no significant 
influence on the log EC50 value. 
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Table 2.2: Analysis of six different co-expression systems of CBRs in Sf9 cells  
 
 
Steady-state GTPase assay was performed as described in Materials and Methods. Each membrane preparation additionally contained Gβ1γ2 protein. Reaction 
mixture contained CP 55,940 concentrations from 1 nM to 10 µM to generate sigmoidal concentration-response curves. Data were analyzed by nonlinear 
regression and best fit to sigmoidal concentration-response curves. Data shown are the mean values ± SD of 3 - 9 independent experiments performed in 
triplicates with three different membrane preparations. Statistical significance was determined by the one-way ANOVA, followed by the Dunnett´s multiple 
comparison test. Stimulation of GTPase activity was significantly higher in the Gαi2 + RGS4 system with p values ≤ 0.001 for CB1R and CB2R. Regarding basal 
values of GTPase activity, the CB1R + Gαi2 system with RGS4 and RGS19 shows a significant increase of basal activity (p = 0.0034), whereas in the CB2R + 
Gαi2 system only RGS4 influences basal activity significantly (p < 0.001). The logEC50 of the CB2R + Gαo differed to the logEC50 values of the other CB2R co-
transfection systems (p = 0.0136).  
(no symbol: not significant; *p ≤ 0.05, **p ≤0.01, ***p ≤0.001) 
 
hCB1R  hCB2R 
 
Basal CP 55,940 10 µM logEC50  Basal CP 55,940 10 µM logEC50 
 
membrane 
[pmol x mg-1  
x min-1] 
[pmol x mg-1 
x min-1] 
[% change of 
basal activity]  
 [pmol x mg-1  
x min-1] 
[pmol x mg-1  
x min-1] 
[% change of 
basal activity]  
Gαo 2.08 ± 0.76 2.44 ± 0.81 19 ± 9 -7.45 ± 0.90  0.59 ± 0.12 0.75 ± 0.17 27 ± 6 -8.73 ± 0.41* 
Gαo + RGS4 3.38 ± 1.27 5.33 ± 2.04 67 ± 21 -7.81 ± 0.43  0.73 ± 0.40 1.13 ± 0.63 57 ± 17 -8.38 ± 0.49 
Gαo + RGS19 2.91 ± 0.86 4.34 ± 1.34 49 ± 4 -7.74 ± 0.27  0.95 ± 0.25 1.26 ± 0.40 31 ± 11 -7.86 ± 0.43 
Gαi2 3.77 ± 0.48 5.69 ± 0.50 53 ± 19 -8.07 ± 0.07  1.07 ± 0.45 1.81 ± 0.78 70 ± 13 -8.29 ± 0.30 
Gαi2 + RGS4 5.40 ± 0.02** 13.95 ± 0.38 158 ± 8*** -7.86 ± 0.08  3.20 ± 0.46*** 8.14 ± 0.77 156 ± 15*** -7.94 ± 0.14 
Gαi2 + RGS19 5.60 ± 0.92** 8.53 ± 0.86 55 ± 8 -8.02 ± 0.28  1.48 ± 0.56 2.50 ± 0.80 69 ± 11 -7.92 ± 0.65 
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2.4.5 Evaluation of solvent effects in the steady-state GTPase assays 
As ligands of CBRs are usually lipophilic, the use of BSA (Breivogel, 2006) or 
organic solvents like DMSO is often necessary to avoid solubility problems. 
Therefore, we evaluated the effect of either 0.1 mg/ml BSA or 3% DMSO (v/v) (final 
concentrations) on the outcome of the steady-state GTPase assays using the ligands 
anandamide, CP 55,940 and WIN 55,212-2 (Table 2.3). For these evaluations, we 
used the CBR + Gαi2 + Gβ1γ2 + RGS4 co-expression system. The use of BSA 
solution resulted in an increase of GTPase stimulation except for CP 55,940 at the 
CB1R, a finding, we do not have a plausible explanation for. A better solubilisation 
under modified physiochemical conditions can be discussed. The logEC50 values 
were mostly not affected (no statistical significance). An exception is WIN 55,212-2 in 
the CB1R system. Its BSA logEC50 value differs significantly with a p value of 0.0482 
from the DMSO logEC50 value.  
 - 46 - 
 
 
 
Table 2.3: Comparison of two solvents on GTPase activity of CB1R and CB2R co-expressed with Gαi2 + Gβ1γ2 + RGS4 in Sf9 cells 
 
  
hCB1R  hCB2R 
ligand solvent 
Basal 
[pmol x mg-1 x min-1] 
GTPase 
stimulation [%] log EC50 
 Basal 
[pmol x mg-1x min-1] 
GTPase 
Stimulation [%] log EC50 
anandamide 
 
DMSO 
BSA 
6.01 ± 1.40 82 ± 26 
139 ± 13 
-6.66 ± 0.20 
-6.49 ± 0.42 
 
2.64 ± 0.63 73 ± 13 
190 ± 32 
-6.22 ± 0.33 
-5.42 ± 0.23 4.88 ± 0.80  2.52 ± 0.98 
CP 55,940 
 
DMSO 
BSA 
5.40 ± 0.02 158 ± 8 
152 ± 4 
-7.86 ± 0.08 
-7.94 ± 0.10 
 
3.20 ± 0.46 156 ± 15 
190 ± 8 
-7.94 ± 0.14 
-7.90 ± 0.12 5.15 ± 0.21  2.74 ± 0.39 
WIN 55,212-2 
 
DMSO 
BSA 
6.60 ± 1.13 94 ± 18 
153 ± 26 
-7.34 ± 0.12* 
-7.14 ± 0.06* 
 
2.28 ± 0.40 161 ± 33 
218 ± 32 
-8.54 ± 0.24 
-8.10 ± 0.27 4.88 ± 0.87  2.67 ± 1.13 
 
Steady-state GTPase assay was performed as described in Materials and Methods. Reaction mixtures contained CP 55,940 concentrations from 1 nM to 
10 µM to generate sigmoidal concentration-response curves. Data were analyzed by nonlinear regression and best fit to sigmoidal concentration-response 
curves. Results shown are mean values ± SD and represent 3 independent experiments performed in triplicates with different membrane preparations. 
Statistical evaluation was performed with the Student´s t-test. No significant difference of the logEC50 values could be determined between DMSO and BSA. 
Only the logEC50 value of WIN 55,212-2 showed a significant difference in the tested solvents in the CB1R system (p = 0.0482). (unpaired Student´s t test, *p ≤ 
0.05) 
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2.4.6 Analysis of potencies and efficacies of CBR ligands in the functional 
steady-state GTPase assay 
The most efficient activation of GTPase by the Gαi2 + Gβ1γ2 + RGS4 construct 
directed us to choose this model for further validation of the test system with several 
ligands (Table 2.4) using the plant-derived agonist ∆9-THC, the endogenous agonists 
anandamide and 2-AG, the synthetic agonists CP 55,940 and WIN 55,212-2 as well 
as the synthetic inverse agonists AM 251 and AM 281 (at CB1R) and antagonist 
AM 630 (at CB2R). According to the two-state model of GPCR activation (Seifert and 
Wenzel-Seifert, 2002), agonists stabilize the active R* state and increase basal 
G protein activity, whereas inverse agonists stabilize the inactive R state and 
decrease basal G protein activity. Antagonists do not change this equilibrium. 2-AG, 
the most abundant endogenous agonist, acted as a full agonist with similar potency 
at both CBRs. Emax values of all other agonist at a concentration of 10 µM were 
related to the GTPase activation by 2-AG (Emax set 100%). ∆9-THC acted as partial 
agonist at CBRs showing a higher efficacy at CB1R than CB2R (47 ± 3% versus 29 ± 
4%, respectively) which finding is in accordance with literature data (McPartland and 
Glass, 2003; Pertwee 2008a). Anandamide acted as a partial agonist at CB1R (79 ± 
25%) and at CB2R (55 ± 10%). WIN 55,212-2 behaved as a nearly full agonist at the 
CB1R (90 ± 17%) and as a “superagonist”, with stimulation of GTPase higher than 2-
AG, at the CB2R (122 ± 25%). CP 55,940 showed very similar increase of GTPase 
activity at both receptors (158 ± 8% versus 156 ± 15%). Compared to 2-AG, 
CP 55,940 acted as “superagonist” at both receptors (152 ± 8% at the CB1R and 
118 ± 11% at the CB2R).  
Decrease of GTPase activity was observed by the inverse agonists AM 251 
and AM 281 at the CB1R. Emax values of these ligands were related to the GTPase 
inhibition by AM 251 that showed the strongest reduction of GTPase activity (Emax set 
-100%). In relation to AM 251, AM 281 caused a decrease of GTPase activity to -84 ± 
5%. An influence of GTPase activity with AM 630 was only observed when tested in 
the presence of 30 nM CP 55,940. Under these conditions AM 630 reduced GTPase 
activity to basal GTPase activity assessed with 3% (v/v) DMSO. With this 
experimental design, the reversibility of agonist CP 55,940 effect by an antagonist 
can be demonstrated. AM 630 inhibited GTPase stimulation by CP 55,940 with a Kb 
value of 632 ± 93 nM. The same procedure was performed for the CB1R, where 
AM 251 competed with CP 55,940 and consequently reduced the enhanced GTPase 
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activity. The Kb value for AM 251 at the CB1R was 52 ± 6 nM. Figure 2.4 shows 
typical concentration-response curves for selected CBR ligands. 
 
 
Table 2.4: Analysis of potencies and efficacies of CBR ligands in the functional steady-state 
[γ-32P]GTPase assay 
 
 
 
Regulation of GTPase activity by different CBR ligands compared to basal GTPase activity assessed 
with 3% (v/v) DMSO. Steady-state GTPase assay was performed as described in Materials and 
Methods. Emax values represent the stimulation of ligands [10 µM] relative to the endogenous agonist 
2-AG (defined as 100% response) respectively the inhibition relative to AM 251 (defined as -100% 
inhibition). Reaction mixtures contained CBR ligands at various concentrations (1 nM - 10 µM). Data 
were analyzed by nonlinear regression and best fit to sigmoidal concentration-response curves. Basal 
activities ranged between 5.11 and 7.71 pmol x mg-1 x min-1 for CB1R and between 1.57 and 3.33 pmol 
x mg-1 x min-1 for CB2R. The maximal stimulatory effect of 2-AG constituted 65 to 137% for CB1R and 
116 to 148 % for CB2R over basal. The results are expressed as mean values ± SD and represent 3 
independent experiments performed in triplicates with different membrane preparations.  
* Data determined in the presence of 30 nM CP 55,940, ** not determined,  
1 Pertwee, 1999, 2 Mechoulam et al., 1995, 3 Lan et al., 1999a, 4 Lan et al., 1999b, 5 Ross et al., 1999 
  
  
ligand 
Gαi2 + 
Gβ1γ2 
+ RGS4 
GTPase 
stimulation / 
inhibition [%] 
Emax 
[%] 
logEC50 / 
logIC50 
logIC50 
(literature) 
∆
9
-THC CB1R 49 ± 3 47 ± 3 -7.13 ± 0.14 -7.271 
 CB2R 38 ± 5 29 ± 4 -6.77 ± 0.08 -7.121 
anandamide CB1R 82 ± 26 79 ± 25 -6.66 ± 0.20 -7.051 
 CB2R 73 ± 13 55 ± 10 -6.22 ± 0.33 -6.431 
2-AG CB1R 104 ± 14 100 -6.02 ± 0.35 -6.332 
 CB2R 132 ± 13 100 -5.73 ± 0.25 -5.852 
CP 55,940 CB1R 158 ± 8 152 ± 8 -7.86 ± 0.08 -8.301 
 CB2R 156 ± 15 118 ± 11 -7.94 ± 0.14 -8.741 
WIN 55,212-2 CB1R 94 ± 18 90 ± 17 -7.34 ± 0.12 -6.911 
 CB2R 161 ± 33 122 ± 25 -8.55 ± 0.24 -8.391 
AM 251 CB1R -73 ± 3 -100 -7.44 ± 0.06 -8.133 
AM 281 CB1R -61 ± 4 -84 ± 5 -7.64 ± 0.09 -7.924 
AM 630* CB2R -48 ± 8 n.d.** -5.94 ± 0.33 -7.515 
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Figure 2.4: Representative concentration-response curves obtained in the steady-state GTPase 
assay with CBRs co-expressed with Gαi2 + Gβ1γ2 + RGS4 in Sf9 cells  
GTPase activity was determined as described in Materials and Methods. Data show merged results of 
3 independent GTPase assays obtained from different ligands in concentrations indicated on the 
abscissa. A Effects of CP 55,940 (●), ∆9-THC (□) and AM 251 (▲) on GTPase activity in Sf9 cells co-
expressing CB1R + Gαi2 + Gβ1γ2 + RGS4. B Effects of AM 251 (▲) on GTPase activity in the 
antagonist mode in the presence of 30 nM CP 55,940. C Effects of CP 55,940 (●), ∆9-THC (□) and AM 
630 (♦) on GTPase activity in Sf9 cells co-expressing CB2R + Gαi2 + Gβ1γ2 + RGS4. D Effect of AM 
630 (♦) on GTPase activity in the antagonist mode in the presence of 30 nM CP 55,940. 
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2.4.7 Analysis of C. sativa extract in the functional steady-state GTPase assay 
As natural compounds always occur in a matrix of other secondary metabolites 
we evaluated whether this system is sensitive enough to detect an agonist at CBRs 
in a mixture of other compounds. Therefore we added 10% (m/m) ∆9-THC artificially 
to a ∆9-THC free cannabis extract and obtained the expected increase of GTPase 
activity (Figure 2.5).  
 
 
 
Figure 2.5: Effect of C. sativa extract in the steady-state GTPase assay 
GTPase activity was determined as described in Materials and Methods. Data show the merged 
results of 3 independent GTPase assays obtained for a ∆9-THC free C. sativa extract (■) and C. sativa 
supplemented with 10% ∆9-THC (▲) in Sf9 cell membranes co-expressing CB1R + Gαi2 + Gβ1γ2 + 
RGS4 (A) and CB2R + Gαi2 + Gβ1γ2 + RGS4 (B). 
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2.4.8 Analysis of dodeca-2E,4E-dienoic acid isobutylamide and Echinacea 
purpurea extract 
The analysis of the CB2R ligand dodeca-2E,4E-dienoic acid isobutylamide 
(Raduner et al., 2006) revealed lacking effects in the GTPase assay. Even in the 
presence of 10 nM CP 55,940, a test mode in which a neutral antagonist can be 
characterized, no effect was detectable (Figure 2.6A). Furthermore, the lipophilic 
hexane extract of Echinacea purpurea roots containing several alkamides (Perry et 
al., 1997) showed no activity in the GTPase assay, also tested in both modes 
(Figure 2.6B).  
 
 
Figure 2.6: Effect of dodeca-2E,4E-dienoic acid isobutylamide and Echinacea purpurea root 
hexane extract on GTPase activity of the CB2R 
GTPase activity was determined as described in Materials and Methods. Data show a representative 
result performed in triplicates in Sf9 cells expressing CB2R + Gαi2 + Gβ1γ2 + RGS4. The experiment 
was replicated 3 independent times with different membrane preparations. 10 µM CP 55,940 was 
used as a positive control (▼). A, effect of dodeca-2E,4E-dienoic acid isobutylamide on GTPase 
activity (●) and in the antagonist mode in the presence of 10 nM CP 55,940 (○). B, effect of Echinacea 
purpurea root hexane extract on GTPase activity (■) and in the antagonist mode in the presence of 
10 nM CP 55,940 (□). 
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2.5 Discussion 
In this study a functional steady-state GTPase test system for the 
pharmacological characterization of known CB1R and CB2R ligands, as well as for 
functional studies and the search of new agonists and antagonists in complex natural 
matrices was established and validated. The assay was developed by using different 
cell lines or tissues endogenously or heterogeneously expressing CBR. Efforts were 
made to establish this highly sensitive assay efficient at mammalian test systems, but 
the superior expression of CBRs in Sf9 cells and the use of the baculovirus 
expression system offered a unique chance to analyze ligands, even partial agonists 
and inverse agonists. 
Using membranes of CBR transfected HEK 293 cells did not lead to a 
successful outcome. Imaging of the transfected HEK 293 cells illustrates the 
difference of CB1R and CB2R concerning their basal localization. Like in our present 
study, the localization of CB1R in intracellular vesicles was already reported earlier 
(Leterrier et al., 2004). Possibly, the high constitutive CB1R activity results in 
constitutive internalization and constitutive desensitization with subsequent G protein 
uncoupling and lack of GTPase activation as was previously shown for a 
constitutively active β2 adrenergic receptor mutant (Pei et al., 1994). However, in Sf9 
cells, desensitization and internalization of GPCRs is much less pronounced. In fact, 
even in the presence of agonists, usually resulting in desensitization, enhanced 
GPCR expression is observed (Schneider et al., 2009; Gether et al., 1997). 
Establishing the steady-state GTPase assay in rat tissue membranes, only 
cerebellum membranes led to the expected effect of the tested ligands. Suppression 
of ligand-independent GTPase activity with NaCl increased the effect of a full agonist 
such as CP 55,940 in a manner that a measurement of GTPase stimulation was 
quite possible. However, for qualitative analysis of a partial agonist or a partial 
inverse agonist the sensitivity of the rat cerebellum membrane system was 
insufficient and the use of rat spleen membranes did not lead to a successful 
outcome. Therefore, we established the [35S]GTPγS binding assay with mammalian 
membranes endogenously expressing CBRs that is described as a highly sensitive 
assay with a better signal-to-noise ratio than the GTPase assay (Seifert et al., 1998; 
Gierschik et al., 1989). In agreement with other systems, GDP reduced basal GTPγS 
binding in rat cerebellum and rat spleen membranes. In contrast to previously 
published experiments – such as in CHO cell membranes (Ross et al., 1999) - GDP 
Chapter 2: Establishment of recombinant CBR assays 
 
- 53 - 
 
did not unmask an agonist effect on GTPγS binding. Possibly, the density of CBRs 
and/or the cognate coupling G proteins in rat cerebellum is too low. The lack of 
agonist response in these test systems indicates that the use of mammalian tissues 
expressing CBRs is not suitable for detailed functional and pharmacological studies.  
Furthermore, the use of rat tissue for pharmacological screening studies is less 
satisfactory than transfected cell membranes. Although rat brain is highly populated 
with CB1Rs, CB2Rs are expressed in brain as well (Skaper et al. 1999). Along the 
same line in spleen, although most of the CBRs present in this system are CB2Rs, 
some CB1Rs are expressed, too (Howlett et al., 2002). 
 The use of Sf9 cells and the baculovirus expression system offers several 
advantages. These insect cells do not possess mammalian G proteins or GPCRs, 
especially the absence of CBRs is described in literature (McPartland et al., 2001), 
and - in contrast to a mammalian cell line - the production of endogenous ligands can 
be excluded. The experimental design ensures that data are not influenced by 
fluctuating conditions of a living cell. Hence, by co-infection of baculoviruses 
encoding for a certain GPCR and G proteins, functional studies can be performed 
(Nickl et al., 2008; Wenzel-Seifert and Seifert, 2003) without the background noise of 
endogenously existing, potentially constitutively active receptors. Furthermore, it is 
relatively insensitive in terms of solvents, affords easy reconstitution of GPCRs and 
G proteins and enables high GPCR expression (6.6 ± 0.9 pmol/mg CB1R and 3.4 ± 
1.7 CB1R) and Gαi2 protein expression (480 ± 34 pmol/mg in CB1R membranes and 
167 ± 68 pmol/mg in CB2R membranes) expression. Also, the Gβγ subunit protein 
expression (5.8 ± 1.2 pmol/mg in CB1R membranes and 4.3 ± 1.5 pmol/mg in CB2R 
membranes) is in a similar expression level as the receptor proteins (Nickl et al., 
2008).  
However, the use of insect cells renders the assay somewhat artificial due to 
the fact that in native mammalian cells different Gα subunits as well as several 
proteins with RGS domains are expressed in parallel (Burchett 2000). A highly 
specific interaction of a compound via a certain Gα subunit and/or a certain RGS 
protein (Seifert and Dove 2009) cannot be excluded so that a lacking activity in a 
defined G protein co-expression system and the respective assay is not a general 
proof of lacking activity at the receptor. Furthermore, misfolding or proteolysis of 
expressed proteins had to be considered. Another matter of fact that should be kept 
in mind is, that the efficiency of coupling between the receptors and the Gα subunit 
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depends on the density of the subunit in the membrane and its proximity to the 
receptors. This proximity of the signaling partners is necessary for forming the 
ternary complex which is a crucial step in the G protein cycle and therewith allowing 
the measurement of GTPase activity. As already published (Nickl et al., 2008), the 
Gα subunit in the established assay is expressed at a high level with a GPCR-Gα 
subunit ratio of 1:73 (CB1R) and 1: 48 (CB2R). This ensures statistical room for 
coupling of the Gα subunit to the receptor. Anyway, a defined 1:1 stoichiometry and a 
close proximity of the receptor and the Gα subunit would be guaranteed by GPCR-
Gα fusion proteins and is an interesting further development for the characterization 
of ligands to CBR in the steady-state GTPase (Seifert et al., 1999b). 
As CBRs are Gi/0 protein coupled GPCRs, in a first step, Gα0 and Gαi2 subunits 
as well as two RGS proteins, RGS4 and RGS19, were co-expressed to develop an 
assay with high GTPase activity and thus a high sensitivity required for a screening 
procedure usually applied for a bioactivity-guided isolation of natural products. The 
construct of CBR + Gαi2 + Gβ1γ2 + RGS4 was the most efficient system. This is in 
accordance with literature data (Kleemann et al., 2008) where the RGS4 protein 
enhanced the absolute and relative values of GTPase stimulation with an increase of 
the basal GTPase activity values. This increase of GTPase stimulation could be 
observed in our CBR assay system, resulting in a higher sensitivity. These data also 
imply that under our assay conditions, GTP hydrolysis can become the rate-limiting 
step of the G protein cycle (Schneider and Seifert 2009; Kleemann et al., 2008). The 
optimized assays allow the characterization of ligands as partial, full or inverse 
agonists and antagonists at a very proximal point of the signal cascade of GPCRs. 
Various agonists, inverse agonists and antagonists like anandamide, 2-AG, ∆9-THC, 
CP 55,940, WIN 55,212-2, AM 251, AM 281 and AM 630 were characterized to 
ensure the validity of the test systems. In agreement with the literature, ∆9-THC was 
characterized as partial agonist with higher affinity to CB1R than to CB2R (McPartland 
and Glass, 2003; Pertwee, 2008b). CP 55,940 and WIN 55,212-2 are full agonists at 
CB1R with EC50 values in the low nM range, also matching the literature data (Felder 
et al., 1995, Griffin et al 1998). AM 251 and AM 281 were described as selective 
CB1R antagonists with strong inverse agonist properties (Cosenza et al., 2000). This 
finding was also demonstrated in our assay as both reduced CB1R GTPase activity 
by 73 ± 3 % and 61 ± 4%, respectively with AM 251 being the more efficacious 
inverse agonist. In our assay AM 630 behaved as a neutral CB2R antagonist with 
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reduction of GTPase activity of -48 ± 8% in the presence of 30 nM CP 55,940. This is 
in contrast to literature data, where AM 630 is described as a antagonist of CB2R with 
the properties of an inverse agonist (Howlett et al., 2002; Ross et al., 1999). For a 
final conclusion of its pharmacological behavior further experiments are required. The 
Kb values of 52 ± 6 nM for AM 251 and 632 ± 93 nM for AM 630 determined in our 
hands differ considerably compared to published data, where the pharmacological 
parameters of these ligands were evaluated in CBR competition binding experiments 
(Lan et al., 1999a; Ross et al., 1999). For AM 251 a Ki value of 7.49 nM (Lan et al., 
1999) and for AM 630 a Ki value of 31 nM (Ross et al., 1999) can be found in 
literature. In addition to the fact, that these literature values were not determined in a 
functional assay but in CBR competition binding assays with different assay 
conditions, this discrepancy can be explained by the concept of ligand specific 
receptor conformation. As it is described for example for the β2 adrenergic receptor 
(Seifert et al. 2001) and the histamine H4 receptor (Schneider et al., 2009), ligands 
can stabilize unique receptor confirmations. It is possible that in our assay the 
agonist CP 55,940, stabilizes a specific GDP/GTP exchange-promoting conformation 
of the GPCR for which the affinity of the inverse agonist/antagonist is lower as 
compared to the CP 55,940 conformation detected in the radioligand binding assay 
(Lan et al., 1999; Ross et al., 1999). In accordance with these dissociations between 
functional Kb values and Ki values in ligand binding experiments at CBRs, we 
observed dissociations between receptor conformations with respect to high-affinity 
agonist binding and GDP/GTP exchange at a constitutively active mutant of the 
β2 adrenergic receptor (Seifert et al., 2001) 
In accordance with the literature data, anandamide acted as a partial agonist at 
both receptors (Howlett et al., 2002). Furthermore, Song et al. (1999) showed that 
WIN 55,212-2 was more efficacious at CB2R, explaining this finding by an amino acid 
residue change from valine in CB1R to phenylalanine in CB2R at position 46 in 
transmembrane helix 5. This finding could also be replicated in our established 
functional assay, where WIN 55,212-2 showed the characteristics of a full agonist at 
the CB1R and a “superagonist” at the CB2R. In our assay CP 55,940 acted on both 
CBR with very similar affinity, a finding that was expected since an equal binding 
affinity on both receptors was published in several papers (Thomas et al., 1998; 
Pertwee, 2008a). Compared to the endogenous ligand 2-AG, in our test system 
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CP 55,940 behaved like a “superagonist” at both receptors with an increase of 
GTPase activity with 51% at the CB1R and 18% at the CB2R more than 2-AG. 
The validation also included the influence of the solvent enhancer DMSO and 
BSA due to the fact that the ligands of CBRs are often lipophilic and thus not 
quantitatively water-soluble. DMSO did not affect the outcome up to a concentration 
of 3% (v/v) and BSA was usable in a concentration of 1 mg/ml as recommended by 
Breivogel (Breivogel, 2006). We recommend the use of DMSO due to the fact that 
lipophilic, unsaturated compounds undergo the risk of binding and autoxidation 
processes in highly concentrated protein solvents like BSA and FCS containing for 
example Fe2+/Fe3+ ions. Furthermore, the handling of DMSO solutions is easier 
because BSA causes foamy solutions after mixing which makes it more difficult to 
pipette accurately and tends to absorb to plastic which might influence the final BSA 
concentration. 
The assay was sensitive enough to detect the partial agonist ∆9-THC in a matrix 
of a ∆9-THC free Cannabis extract and thus it is usable for a bioactivity-guided 
fractionation protocol for natural products (Heilmann, 2007). A more complex 
problem and a limitation for such a screening procedure could be the possible 
simultaneous presence of antagonists and agonists in the matrix which can abolish 
or mask the GTPase activity.  
The recently identified CB2R ligand dodeca-2E,4E-dienoic acid isobutylamide 
isolated from Echinacea purpurea (Raduner et al., 2006) as well as a Echinacea 
purpurea root extract containing several other alkamides (Perry et al., 1997) was 
tested for agonism, neutral antagonism and inverse agonism in our GTPase assay 
and showed no activity in all modes with the used membrane construct. This is in 
contrast to literature data where not only binding, but also CB2R-dependent effects 
have been reported in mammalian cellular systems for dodeca-2E,4E-dienoic acid 
isobutylamide. Raduner et al. (2006) measured elevated intracellular Ca2+ 
concentration in CB2-positive cells, an effect that was inhibited by the CB2R 
antagonist SR144528. It can be discussed that a highly cell-specific coupling to a  
G protein heterotrimer subunit is necessary for the effect of the alkamides.  
For further prospective GPCR-Gα fusion proteins for characterization of CBRs 
are in progress. 
In conclusion, we established and validated a steady-state GTPase assay for 
hCBRs as a highly sensitive test system that allows the characterization of ligands at 
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a very proximal point of the signal cascade of this type of GPCRs. Efforts were made 
to establish a functional assay in mammalian tissue membranes, but the resulting 
signal were far too small. Showing very sensitive and practical properties, the test 
system with CBR expressing Sf9 cell membranes is also suitable for screening 
procedures and bioactivity-guided isolation of natural compounds. 
 
. 
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3 Impact of fusion to Gαi2 and co-expression with RGS proteins on 
pharmacological properties of human cannabinoid receptors 
CB1R and CB2R* 
3.1 Abstract 
G protein coupled receptor (GPCR)-Gα
 
fusion proteins are often employed to 
investigate in detail receptor-G protein interaction. In the current study, the impact of 
Gα fusion proteins on the pharmacology of CBRs, both mediating signals through Gαi 
proteins, were investigated. The Gαi2 protein was fused to the C-terminus of the 
CBRs or co-expressed with non-fused Gαi2 in Sf9 cells, always together with Gβ1γ2. 
As it is known that RGS proteins can regulate the sensitivity of G protein pathways, 
the impact of these proteins on CBR signaling in combination with the fusion 
approach was examined as well, using RGS4 and RGS19 as paradigms. Known 
CBR ligands were characterized in the steady-state GTPase assay and 
pharmacological properties of ligands in the different test systems were correlated. 
These studies showed the following: Fusion of CBRs to Gαi2 enhanced the maximal 
stimulatory effects of ligands compared to the co-expression system, especially for 
the CB2R. RGS4, but not RGS19 behaved as a GTPase activating protein at CBRs in 
the Gαi2 co-expression and fusion system. Fusion of GPCR, most prominently CB2R, 
to Gαi2 and co-expression with RGS4 altered the pharmacological properties of 
ligands. Our data suggest that fusion of CB2R to Gαi2 and co-expression with RGS4 
impedes with conformational changes. Moreover, our results support the concept of 
ligand-specific receptor conformation because not all ligands are altered similarly. 
 
 
                                            
* This chapter is adapted from: Sutor S, Heilmann J, Seifert R (2010) Impact of fusion to Gαi2 and co-
expression with RGS proteins on pharmacological properties of human cannabinoid receptors 
CB1R and CB2R (submitted to Naunyn Schmiedebergs Arch Pharmacol) 
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3.2 Introduction 
Many hormones and neurotransmitters exert their physiological effects through 
GPCRs. G proteins play an important role as mediators of signals between GPCRs 
and intracellular effector molecules. The binding of an agonist to a GPCR induces a 
conformational change accompanied by the exchange of bound GDP to GTP and 
dissociation of the Gα-GTP-Gβγ complex into the subunits Gα-GTP and Gβγ (Gille 
and Seifert, 2003). Both subunits can regulate effector systems, for example adenyly 
cyclase- and mitogen-activated protein (MAP) kinase activity in the case of Gαi. 
Deactivation of the G protein is accomplished by the intrinsic GTPase activity of the 
Gα subunit, hydrolyzing GTP to GDP and Pi. Subsequently, reassociation of Gα, 
GDP and Gβγ completes the G protein cycle. According to the two-state model of 
GPCR activation (Seifert and Wenzel-Seifert, 2002), agonists stabilize the active R* 
state and increase basal G protein activity, whereas inverse agonists stabilize the 
inactive R state and decrease basal G protein activity. Antagonists do not change this 
equilibrium. Refinements of this two-state model were derived from observations of 
agonist-specific trafficking of a receptor stimulus. In accordance with this model, each 
agonist is capable of stabilizing or selecting a unique receptor conformation, which 
results in an unlimited number of active receptor states (Kenakin, 1995).  
The efficacy of receptor-G protein coupling is highly influenced by protein 
expression levels and stoichiometry of signaling partners (Seifert et al., 1999). One 
limitation concerning the use of GPCR co-expression systems in assay development 
or functional studies is the lacking guarantee that every receptor molecule is spatially 
associated with its signaling partner. The use of receptor-Gα fusion proteins offers 
the advantage of a defined stoichiometry combined with a close proximity of GPCR 
and G protein (Seifert et al., 1999; Milligan, 2000). As the binding of ligands is 
accompanied by a conformational change in receptors, it is of substantial interest 
whether the pharmacological properties of ligands and receptors are influenced by 
the fusion to the Gα subunit. Some authors reported on alterations in 
pharmacological properties of ligands of the α2A adrenoceptor as a result of the 
fusion (Burt et al., 1998), whereas for others like the 5-HT1A receptor, similar 
potencies and efficacies were observed (Kellett et al., 1999). 
To address this question for the two human cannabinoid receptors (CBRs), 
which belong to family A GPCRs and couple to pertussis-toxin (PTX) sensitive Gαi/o 
(Howlett et al., 2002), receptors were fused C-terminally to the N-terminus of the Gαi2 
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subunit. Afterwards the pharmacological properties of the endogenous agonists 
anandamide and 2-arachidonoyl glycerol (2-AG), the synthetic agonists CP 55,940 
((-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) 
cyclohexanol) and WIN 55,212-2 ((R)-(+)-[2,3-dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1 naphthalenylmethanone 
mesylate), as well as the synthetic inverse agonists AM 251 (N-(piperidin-1-yl)-5-(4-
iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) and AM 
281 (1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-
3-carboxamide) (at CB1R) and antagonist AM 630 (6-iodo-2-methyl-1-[2-
4(morpholinyl)-ethyl]-[1H-indol-3-yl]-(4-methoxyphenyl)methanone) (at CB2R), were 
determined. To examine the potencies and efficacies of these ligands, the steady-
state GTPase assay, a reliable and sensitive assay system, was employed (Geiger et 
al., 2010; Seifert and Wenzel-Seifert, 2002). Data obtained in the fusion protein 
system were compared with those obtained in a system where the CBRs were co-
transfected with the Gαi2 subunit.  
Regulators of G protein signaling (RGS) proteins are a protein family 
regulating the sensitivity of G protein signaling pathways. RGS proteins can serve as 
GTPase activating protein (GAPs) for Gα subunits (Wettschureck and Offermanns, 
2005) and shorten the period of time in which the Gα subunit is in its active 
conformation. Thereby, RGS proteins facilitate GPCR signal termination. Studies with 
RGS proteins revealed that GTP hydrolysis can become the rate-limiting step of the 
G protein cycle and that the G protein GTPase kinetics are altered by RGS proteins 
(Kleemann et al., 2008; Schneider and Seifert, 2009). GAP activity of RGS proteins, 
as key modulators in amplitude and duration of G protein mediated signaling, were 
described for Gαi and Gαq subunits (Hollinger and Hepler, 2002).  
As it has been reported that RGS4 and RGS19 are GAPs for the Gαi subfamily 
(Berman et al., 1996) and that RGS proteins can participate in the formation of a 
quaternary complex consisting of agonist, receptor, G protein and RGS protein 
(Benians et al., 2005), another aim of this study was to investigate the influences of 
these RGS proteins on the pharmacological properties of CBR ligands in fusion and 
co-expression systems. Therefore, Spodoptera frugiperda (Sf9) cells were infected 
with baculoviruses encoding for CBRs-Gαi2 or CBRs co-transfected with Gαi2 always 
together with Gβ1γ2 and in the absence or presence of RGS4 or RGS19. 
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3.3 Materials and Methods 
3.3.1 Materials 
The DNA primers for PCR were synthesized by MWG Biotech (Ebersberg, 
Germany). PfuUltra II fusion HS polymerase was from Stratagene (La Jolla, CA, 
USA). Restriction enzymes were purchased from New England Biolabs (Ipswich, MA, 
USA). Recombinant baculovirus encoding Gαi2 was generously provided by Dr. A. G. 
Gilman (Department of Pharmacology, University of Texas Southwestern Medical 
Center, Dallas, TX, USA). Recombinant baculovirus encoding Gβ1γ2 was a kind gift 
from Dr. P. Gierschik (Department of Pharmacology, University of Ulm, Germany). 
Baculoviruses encoding for mammalian RGS4 and RGS19 were a kind gift from Dr. 
E. Ross (Department of Pharmacology, University of Texas Southwestern Medical 
Center, Dallas, TX, USA).  
The M1 anti-FLAG antibody was obtained from Sigma (St. Louis, MO, USA); 
the anti-Gαi2 antibody was purchased from Calbiochem (San Diego, CA, USA).  
Antibodies selective for RGS4 and RGS19 were from Santa Cruz (Santa Cruz, CA, 
USA) and antibody for Gβ subunit (Gβcommon; AS398/9) was kindly provided by Dr. B. 
Nürnberg (Institute of Pharmacology, University of Tübingen, Germany).  
The CBR ligands anandamide, 2-AG, CP 55,940, WIN 55,212-2, AM 251, 
AM 281 and AM 630 were purchased from Tocris Cookson (Ballwin, MO, USA). The 
10 mM stock solutions of these compounds were prepared with 100% (v/v) DMSO 
and dilutions of all ligands were prepared with 30% (v/v) DMSO.  
[γ-32P]GTP was synthesized by enzymatic phosphorylation of GDP and [32P]Pi 
(150 mCi/ml orthophosphoric acid) (PerkinElmer Life Sciences, Boston, MA, USA) as 
described previously (Walseth and Johnson, 1979). Radioactive samples were 
counted in a PerkinElmer Tricarb-TR liquid scintillation analyzer. Unlabeled 
nucleotides were from Roche Diagnostics (Indianapolis, IN, USA), and all other 
reagents were of the highest purity available and from standard suppliers. 
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3.3.2 Methods 
3.3.2.1 Construction of pVL-1392 plasmids encoding SF-hCBR-His6 and SF-hCBR-
His6-Gαi2  
The generation of pVL-SF–hCBR-His6 constructs was previously described 
(Nickl et al., 2008). For preparation of the SF-hCBR-His6-Gαi2 fusion proteins, the 
hexahistidine-tagged C-terminus of hCB1R and hCB2R was fused to the N-terminus 
of Gαi2 according to a previously described strategy using overlap-extension 
polymerase chain reaction (Wenzel-Seifert and Seifert, 2000).  
In PCR 1a, DNA fragments encoding for the cleavable signal peptide from 
influenza hemagglutinin (S), the FLAG epitope (F), the cDNA of CBRs and the 
hexahistidine tag were amplified without stop codons. Therefore, the primers SacI-SF 
(5´-ATC AGA TCA GCT TGA TTC GAG CTC G-3´) and aHis6 (5´-GTG ATG GTG 
ATG ATG GTG-3´), were synthesized, annealing at pVL-1392 plasmids encoding for 
SF–hCB1R-His6 and SF–hCB2R-His6, used as templates in PCR 1a. In PCR 1b, the 
Gαi2 sequence was amplified using a pVL-1392-FPR-His6-Gαi2 template. The sense 
primer for this PCR contained 18 bp encoding for hexahistidine tag (underlined) 
followed by the first 18 bp of the Gαi2 sequence (5´-CAC CAT CAT CAC CAT CAC 
ATG GGC TGC ACC GTG AGC-3´). The antisense primer for SF-hCB1R-His6-Gαi2 
fusion protein aGαi2-XbaI (5´-GGT CGA CTC TAG AGG TCA GAA GAG GCC ACA 
GTC) contained a XbaI site 3´ of the stop codon of Gαi2; the antisense primer for SF-
hCB2R-His6-Gαi2 fusion protein aGαi2-XmaI (5´-ATC CTA CCC GGG TCA GAA GAG 
GCC ACA GTC-3´) contained an extra XmaI site 3´ of the stop codon. In PCR 2, the 
product of PCR 1a and 1b were used as templates together with SacI-SF and aGαi2-
XbaI (for CB1R) respectively aGαi2-XmaI (for CB2R) as primers. PCR 2 resulted in 
fragments, consisting of a signal flag and a FLAG tag, the cDNA for hCBRs, followed 
by a hexahistidine tag and the Gαi2 sequence with a XbaI restriction site for CB1R and 
a XmaI restriction site for CB2R. PCR 2 product containing SF-hCB1R-His6-Gαi2 were 
double-digested with SacI and XbaI and cloned into baculovirus transfer vector pVL-
1392-SF-hCB1R-His6 via SacI and XbaI restriction site; PCR products encoding for 
SF-hCB2R-His6-Gαi2 were double-digested with SacI and XmaI and cloned into 
baculovirus expression vector pVL-1392-SF-hCB2R-His6 via SacI and XmaI 
restriction site. Correct assembly of the constructs was confirmed by extensive 
restriction enzyme analysis and sequencing service of Entelechon (Regensburg, 
Germany). 
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3.3.2.2 Generation of recombinant baculoviruses, cell culture and membrane 
preparation 
Sf9 cells, derived from Spodoptera frugiperda pupal ovarian tissue, were used 
for the baculovirus expression. Sf9 cells were cultured in Erlenmeyer flasks at 28°C 
under rotation at 125 rpm in SF 900 II medium (Life Technology, Carlsbad, CA), 
supplemented with 5% (v/v) fetal calf serum (Pan-Biotech, Aidenbach, Germany) and 
0.1 mg/ml gentamicin sulfate (BioWhittaker, Walkersville, MD). Cells were maintained 
at a density of 0.5-6.0 x 106 cells/ml. Recombinant baculoviruses were generated in 
Sf9 insect cells using the BaculoGOLD transfection kit (BD PharMingen, San Diego, 
CA) according to the manufacturer´s instructions. After initial transfection, high-titer 
virus stocks were generated by two sequential virus amplifications. The supernatant 
fluid of the second amplification was stored under light protection and used as virus 
stock for membrane preparations. 
For membrane preparation, cells were seeded at a density of 3.0 x 106 cells/ml 
and infected with 1:100 dilutions of baculovirus stock solutions of desired proteins. 
Cells were cultured for 48 h and Sf9 membranes were prepared as described 
previously (Geiger et al. 2010) using 1 mM EDTA (Merck, Darmstadt, Germany), 
0.2 mM phenylmethylsulfonyl fluoride (Sigma), 10 µg/ml benzamidine (Sigma) and 
10 µg/ml leupeptin (Calbiochem, San Diego, CA, USA) as protease inhibitors. 
Membranes were homogenized in binding buffer containing 75 mM Tris/HCl, pH 7.4, 
1 mM EDTA and 12.5 mM MgCl2 and stored in aliquots at -80°C. Protein 
concentrations were determined using the DC protein assay kit (Bio-Rad, Hercules, 
CA, USA) according to the instructions of the manufacturer.  
3.3.2.3 SDS-PAGE and immunoblot analysis 
 Membranes were diluted in Laemmli buffer (8 M urea, 2.5% (w/v) SDS, 
200 mM dithiothreitol, 25 mM Tris, 5% glycerol (v/v), 0.01% (w/v) bromophenolblue) 
and separated on SDS polyacrylamide gels containing 12% (w/v) acrylamide 
(Sigma). Proteins were transferred onto 0.45 µm nitrocellulose membranes (Bio-Rad 
Laboratories, Hercules, CA, USA) and then incubated with antibody solution: M1 anti-
FLAG (1:1000), anti-Gαi2 (1:1000), anti-RGS4 (1:500), anti-RGS19 (1:500) and anti-
Gβcommon (1:1200). Protein bands were visualized with Luminol Enhancer Solution 
(Pierce Chemical, Rockford, IL, USA) using anti-mouse IgG (Sigma), anti-goat IgG 
(Santa Cruz, CA, USA) and anti-rabbit IgG (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK), all coupled to horseradish peroxidase. Chemoluminescently 
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stained blots were exposed to Hyperfilms ECL (GE Healthcare) and developed with a 
Cawomat 2000 IR (Böhm Medical, Heiligeneich, Germany). 
3.3.2.4 Steady-state GTPase assay 
The GTPase assay was performed as described (Geiger et al., 2010). Briefly, 
membranes were thawed, sedimented by centrifugation at 18,000 x g for 10 min at 
4°C, and carefully resuspended in 10 mM Tris/HCl, p H 7.4. Assay tubes contained 
membranes (Gαi2 co-transfected membranes 10 µg of protein/tube; Gαi2 fusion 
protein membranes 5 µg of protein/tube), 1.0 mM MgCl2, 0.1 mM EDTA, 0.1 mM 
ATP, 100 nM GTP, 0.1 mM adenylyl imidodiphosphate, 5 mM creatine phosphate, 
40 µg of creatine kinase and 0.2% (w/v) BSA in 50 mM Tris/HCl, pH 7.4, to prevent 
binding of protein or ligand to the polystyrol tubes, and CB1R and CB2R ligands at 
various concentrations. Reaction mixtures (80 µl) were incubated for 2 min at 25°C 
before the addition of 20 µl of [γ-32P]GTP (0.1 µCi/tube). Reactions were conducted 
for 20 min at 25°C for co-transfected membranes and  10 min for fusion protein 
membranes. Reactions were terminated by the addition of 900 µl of slurry consisting 
of 5% (w/v) activated charcoal and 50 mM NaH2PO4, pH 2.0. Charcoal absorbs 
nucleotides but not 32Pi. Charcoal-quenched reaction mixtures were centrifuged for 7 
min at room temperature at 15,000 x g. Six hundred µl supernatant fluid of reaction 
mixtures was removed and 32Pi was determined by Čerenkov radiation in 3 ml water. 
Enzyme activities were corrected for spontaneous degradation of [γ-32P]GTP. 
Spontaneous [γ-32P]GTP degradation was determined in tubes containing all of the 
above described components plus a high concentration of unlabeled GTP (1 mM) 
that, by competition with [γ-32P]GTP, prevents [γ-32P]GTP hydrolysis by enzymatic 
activities present in Sf9 membranes. Spontaneous [γ-32P]GTP degradation amounted 
to <1% of the total amount of radioactivity added. The experimental conditions 
chosen ensured that not more than 20% of the total amount of [γ-32P]GTP added was 
converted to 32Pi. Neutral antagonism property of AM 630 was determined in the 
presence of 30 nM CP 55,940. 
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3.3.2.5 Calculations and statistics 
Data are expressed as means ± SD and represent a minimum of 3 
independent experiments, each performed in triplicate. Statistical evaluations and 
curve fittings were performed using the Prism 4 software (GraphPad Prism, La Jolla, 
CA, USA) and the Microsoft Excel 2007 software. Statistical significance was 
determined by the one-way ANOVA, followed by the Dunnett post test.  
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3.4 Results 
3.4.1 Generation of baculoviruses and detection of protein expression by 
immunoblotting 
 For expression of the human CBRs in insect cells, recombinant baculovirus 
transfer vectors bearing different constructs were designed. To direct the receptor 
protein to the cell membrane and in order to allow immunological detection of the 
recombinant proteins all constructs contained in-frame fusions to a cleavable signal 
peptide from influenza hemagglutinin, followed by the FLAG tag. In plasmids 
encoding for CBRs a hexahistidine tag allowing further purification was fused  
C-terminally to the receptor-coding region. In plasmids encoding for the CBRs-Gαi2 
fusion proteins the hexahistidine
 
tag was used as overlap for the Gαi2 subunit. 
 We transfected Sf9 cells with baculovirus stock solutions encoding for CBRs 
and Gαi2 or the CBR-Gαi2 fusion protein, together with Gβ1γ2 and RGS4 or RGS19 to 
design test systems as described in Table 3.1. Expression of proteins was confirmed 
with immunoblotting. As shown in Figure 3.1A and Figure 3.2A, the M1 anti-FLAG 
antibody recognized the CBRs as well as the CBR-Gαi2 fusion proteins. CB1R 
showed the expected band at ~57 kDa (Xu et al., 2005). Additional bands were 
detected by the M1 antibody, which may reflect oligomeric forms of the CB1R. The 
~41 kDa bands corresponded to CB2R, which is in accordance with literature data on 
the molecular mass of CB2R (Filppula et al., 2004). Regarding fusion proteins, bands 
for CB1R-Gαi2 (~97 kDa) and CB2R-Gαi2 (~80 kDa) appeared as expected. Beneath 
the intense additional bands in CB1R-Gαi2 membranes reflecting oligomeric forms of 
the receptor, a weak band at the level of non-fused CB1R was detected by the M1 
antibody, probably representing a degradation product. Also noticeable is a second 
band for CB2R-Gαi2 which may be due to different glycosylation states of the 
receptor. 
To visualize the Gαi2 subunit, we used an antibody for Gαi1/2 proteins and 
detected intense bands at ~40 kDa in the co-transfection systems and bands 
matching the molecular mass estimation for CB1R-Gαi2 and CB2R-Gαi2 in the fusion 
systems (Figure 3.1B and Figure 3.2B).  
Figure 3.1C shows the detection of Gβ1 with a Gβcommon antibody in the CB1R 
systems. In the CB1R-Gαi2 systems an additional band with relatively high molecular 
mass is particularly evident, whereas for the CB2R protein expression systems 
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(Figure 3.2C) a second weak band near by the band for Gβ1 (~36 kDa) was 
visualized. The identity of these bands is unknown. 
 The detection of co-expressed RGS4 and RGS19 proteins was performed with 
specific anti-RGS4 and anti-RGS19 antibodies (Figures 3.1D and E and Figures 3.2D 
and E). As expected, the bands for RGS4 were about ~1 kDa lower compared to 
RGS19. Additional bands were particularly evident for the anti-RGS19 antibody, 
probably representing oligomeric forms. 
 In conclusion, these data indicate that the desired CBR constructs were 
correctly produced in Sf9 cells after transfection with recombinant baculoviruses and 
that the desired proteins are expressed in the Sf9 membranes. 
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Figure 3.1: Immunoblot analysis of recombinant proteins in Sf9 cell membranes for CB1R test 
systems 
Immunological detection of CB1R, Gαi2, Gβ1γ2 and RGS proteins expressed in Sf9 cell membranes 
was performed as described under Materials and Methods. Each lane was loaded with 10 µg of 
protein. Numbers on the left indicate masses of marker protein in kilodaltons.  A Detection of CB1R 
and CB1R-Gαi2 with the M1 anti-FLAG antibody. B Visualization of Gαi2 with anti-Gαi1/2. C Membranes 
were reacted with Gβcommon antibody. D Detection of RGS4. E Detection of RGS19. 
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Figure 3.2: Immunoblot analysis of recombinant proteins in Sf9 cell membranes for CB2R test 
systems 
Immunological detection of CB2R, Gαi2, Gβ1γ2 and RGS proteins expressed in Sf9 cell membranes 
was performed as described under Materials and Methods. Each lane was loaded with 10 µg of 
protein. Numbers on the left indicate masses of marker protein in kilodaltons. A Detection of CB2R and 
CB2R-Gαi2 with the M1 anti-FLAG antibody. B Visualization of Gαi2 with anti-Gαi1/2. C Membranes were 
reacted with Gβcommon antibody. D Detection of RGS4. E Detection of RGS19. 
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3.4.2 Basal GTPase activity and stimulation of GTPase by CP 55,940 in the 
GTPase assay 
 We performed steady-state GTPase assays with Sf9 membranes co-
expressing the proteins shown in Table 3.1 and determined the maximum stimulatory 
effects of the full agonist CP 55,940. The absolute values of basal GTPase activity 
differed substantially within the different protein combinations and among various 
membranes, reflecting different protein expression levels and/or protein integrities. 
However, in all cases CP 55,940 increased GTPase activity, and addition of RGS4 
markedly enhanced the stimulatory effect of CP 55,940. RGS4, but not RGS19, 
behaved like a GTPase activation protein (Ross and Wilkie, 2000), which is 
statistically verified in Table 3.2 and Table 3.3. Regarding the CB1R system, the 
largest GTPase stimulation was obtained with the fusion system in the presence of 
RGS4. Here, a mean stimulation of 304 ± 9% above basal was calculated. Also for 
the CB2R, the CB2R-Gαi2 fusion protein co-transfected with RGS4 showed the 
highest GTPase stimulation, amounting to 393 ± 30%. 
 Figure 3.3 shows representative concentration-response curves obtained for 
CP 55,940 in systems co-expressing CBR and Gαi2 or expressing CBR-Gαi2 in the 
absence or presence of RGS proteins. Particularly remarkable is the enhanced 
stimulatory effect of the ligand in the CB2R-Gαi2 fusion system. The fusion of CB2R to 
Gαi2 revealed 2.5 – 3-fold higher GTPase activities than in systems where CB2R is 
co-expressed with Gαi2. 
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Figure 3.3: Representative concentration-response curves obtained for CP 55,940 in the Gαi2 
co-expression and Gαi2 fusion system 
Steady-state GTPase activity in Sf9 membranes was determined as described under Materials and 
Methods. Data show representative results performed in triplicates in Sf9 cells expressing CBR + Gαi2 
+ Gβ1γ2 without ●, + RGS4 ■, + RGS19 ▲ or CBR-Gαi2 + Gβ1γ2 without ○, + RGS4 □, + RGS19 ∆. 
Experiments were replicated 3 independent times with different membrane preparations. Reaction 
mixtures contained CP 55,940 at concentrations from 1 nM to 10 µM. Data were analysed by 
nonlinear regression and best fit to sigmoidal concentration-response curves. Pharmacological 
parameters extracted from resulting graphs are shown in Table 3.2 and Table 3.3. 
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Table 3.1: Impact of RGS proteins and of fusion to Gαi2 on the basal GTPase activity and effects 
of full agonist CP 55,940 in the GTPase assay  
  
 
Membrane 
preparation 
number 
Basal 
[pmol x min-1 x mg-1] 
 
Mean value 
basal 
10 µM CP 55,940 
[pmol x min-1 x mg-1] 
% stim 
over 
basal 
CB1R + Gαi2 
1578 5.17 ± 0.12  7.56 ± 0.15 46 
988 2.47 ± 0.07 3.92 ± 1.11 3.95 ± 0.05 60 
1797 4.14 ± 0.08  6.83 ± 0.08 65 
 
CB1R + Gαi2 + RGS4 
 
1794 5.42 ±0.15  13.97 ± 0.12 158 
1579 5.42 ± 0.13 5.40 ± 0.02 13.48 ± 0.11 149 
1798 5.37 ± 0.14  14.40 ± 0.13 168 
CB1R + Gαi2 + RGS19 
1078 4.13 ± 0.12  6.22 ± 0.13 51 
1244 9.68 ± 0.43 6.94 ± 2.29 18.46 ± 0.36 90 
1233 6.95 ± 0.23  11.70 ± 0.20 68 
CB1R-Gαi2 
1722 5.04 ± 0.29  8.39 ± 0.31 67 
1799 5.11 ± 0.33 5.41 ± 0.10 9.56 ± 0.48 87 
1853 5.40 ± 0.19  9.43 ± 0.19 75 
CB1R-Gαi2 + RGS4 
1800 2.42 ± 0.46  10.07 ± 0.38 317 
1841 5.96 ± 0.43 3.49 ± 1.75 23.60 ± 0.45 296 
1848 2.10 ± 0.23  8.41 ± 0.20 299 
CB1R-Gαi2 + RGS19 
1873 7.32 ± 0.32  14.64 ± 0.29 100 
1875 5.12 ± 0.30 5.32 ± 1.56 9.51 ± 0.25 86 
1879 3.52 ± 0.16  7.85 ± 0.14 123 
CB2R + Gαi2 
1580 2.39 ± 0.13  4.61 ± 0.10 93 
1080 1.71 ± 0.11 2.21 ± 0.30 3.16 ± 0.09 86 
1360 2.27 ± 0.07  3.90 ± 0.05 72 
CB2R + Gαi2 + RGS4 
1581 2.92 ± 0.09  7.42 ± 0.06 154 
1624 2.83 ± 0.13 3.20 ± 0.46 7.79 ± 0.11 175 
1857 3.86 ± 0.14  9.20 ± 0.12 139 
CB2R + Gαi2 + RGS19 
1354 1.30 ± 0.06  2.92 ± 0.05 125 
1058 1.63 ± 0.08 1.33 ± 0.24 3.41 ± 0.08 109 
1003 1.04 ± 0.07  1.94 ± 0.05 86 
CB2R-Gαi2 
1849 4.40 ± 0.40  17.14 ± 0.72 290 
1854 6.18 ± 0.64 5.61 ± 0.86 22.04 ± 0.83 257 
1856 6.25 ± 0.49  23.89 ± 0.62 283 
CB2R-Gαi2 + RGS4 
1842 6.93 ± 0.45  33.38 ± 0.53 382 
1817 8.42 ± 0.76 5.83 ± 2.68 39.04 ± 0.94 364 
1850 2.14 ±0.27  11.42 ± 0.44 435 
CB2R-Gαi2 + RGS19 
1874 3.65 ± 0.27  12.97 ± 0.41 256 
1876 4.26 ± 0.47 3.58 ± 0.58 18.28 ± 0.72 330 
1880 2.83 ± 0.38  13.88 ± 0.91 390 
 
Basal and CP 55,940-stimulated GTPase activities in various CBR expressing Sf9 membranes were 
determined as described in Materials and Methods. All membranes expressed proteins given in the 
Table and were additionally co-transfected with Gβ1γ2. Numbers designate the specific membrane 
studied in the GTPase assay. Data shown are the mean ± SD of one assay in triplicates. 
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3.4.3 Potencies and efficacies of standard ligands of the CBRs in the GTPase 
assay in the absence and presence of RGS proteins  
We evaluated the potential effects of GAPs (Ross and Wilkie, 2000) on 
GTPase activity and used RGS4 and RGS19 as paradigms, Gβ1γ2 always being 
present. In previous studies on the chemokine receptor CXCR4 and human histamine 
H4 receptor, both RGS proteins enhanced agonist-stimulated GTP hydrolysis 
(Kleemann et al., 2008; Schneider and Seifert, 2009).  
The potencies and efficacies of several ligands (Table 3.2 and Table 3.3), 
specifically the endogenous agonists anandamide and 2-AG, the synthetic agonists 
CP 55,940 and WIN 55,212-2 as well as the synthetic inverse agonists AM 251 and 
AM 281 (at CB1R) and antagonist AM 630 (at CB2R) were examined. The results 
obtained in the presence of RGS proteins were compared to data evaluated in 
systems where the RGS proteins were absent (CBR + Gαi2 + Gβ1γ2 and CBR-Gαi2 + 
Gβ1γ2, respectively). Regarding CB1R (Table 3.2), no significant changes in 
logEC50/logIC50 values were detected for all analyzed systems. Exceptions are the 
logEC50 of anandamide in the CB1R + Gαi2 + Gβ1γ2 + RGS4- and in the CB1R-Gαi2 + 
Gβ1γ2 + RGS4 system, and the logIC50 of AM 281 in CB1R + Gαi2 + Gβ1γ2 + RGS4 
system.  
All agonists induced relatively small GTPase activations in the standard co-
expression (CB1R + Gαi2 + Gβ1γ2) and standard fusion system (CB1R-Gαi2 + Gβ1γ2) 
and the inverse agonists AM 251 and AM 281 reduced GTPase signals to a similar 
extent. In both systems, addition of RGS4 significantly influenced ligand-regulated 
GTPase activity, resulting in higher stimulation over basal levels for agonists and a 
more effective inhibition of GTPase activity for inverse agonists. A divergent result 
was obtained for anandamide in the co-expression system, where RGS4 did not 
significantly influence GTPase activity (stimulations of 84 ± 25% with RGS4 and 62 ± 
14% in the standard co-expression system), and for the inverse agonist AM 251 in 
the fusion systems (-73 ± 3% with RGS4 and -62 ± 7% in the standard fusion 
system). Interestingly, AM 251, tested in the co-expression system, was the only 
ligand sensitive to RGS19, resulting in a significantly stronger inhibition of GTPase 
activity with a value -80 ± 2% compared to the standard co-expression system with a 
value of -64 ± 4%. For calculation of efficacies, the maximal stimulatory effects of the 
ligands were related to the GTPase activation of 2-AG (Emax set 1.00). Interestingly, 
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only the efficacies of CB1R inverse agonists AM 251 and AM 281 were significantly 
altered by RGS protein addition. 
As was the case for CB1R, RGS4, but not RGS19 enhanced GTPase 
responses of CB2R (Table 3.3). The co-expression of RGS4 enhanced the 
stimulatory effects of all ligands except for anandamide in the co-expression system 
(54 ± 11% stimulation in the standard co-expression system CB2R + Gαi2 + Gβ1γ2 
versus 73 ± 13% in the presence of RGS4) and WIN 55,212-2 in the fusion system 
(192 ± 12% simulation in the standard fusion system versus 255 ± 29% in the 
presence of RGS4). Although for those two compounds the results were not 
statistically significant, a tendency of increasing GTPase activity in the presence of 
RGS4 became apparent. RGS4 altered logEC50 values for anandamide and WIN 
55,212-2 in the co-expression system and RGS19 influenced the logEC50 value for 
CP 55,940 in the fusion system. For anandamide, a logEC50 value of -5.55 ± 0.10 in 
the CB2R + Gαi2 + Gβ1γ2 system was shifted to a logEC50 value of -6.22 ± 0.33 
obtained in the CB2R + Gαi2 + Gβ1γ2 + RGS4 system. Moreover, the potency of WIN 
55,212-2 changed from -8.12 ± 0.07 in the CB2R + Gαi2 + Gβ1γ2 system to -8.55 ± 
0.24 in the system where RGS4 was co-transfected. For CP 55,940 the logEC50 
value of -6.98 ± 0.05 evaluated in the CB2R-Gαi2 + Gβ1γ2 system differs significantly 
from the logEC50 value of -6.60 ± 0.11 obtained in the presence of RGS19. 
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Table 3.2: GTPase activities of standard ligands and impact of RGS proteins in Sf9 cell membranes expressing CB1R co-transfected with Gαi2 or CB1R-Gαi2 
  
CB1R + Gαi2 CB1R + Gαi2 + RGS4 CB1R + Gαi2 + RGS19 CB1R-Gαi2 CB1R-Gαi2 + RGS4 CB1R-Gαi2 + RGS19 
2-AG Stim [%] 50 ± 16 104 ± 14** 59 ± 15 53 ± 8 178 ± 52** 76 ± 8 
 
Emax 1.00 1.00 1.00 1.00 1.00 1.00 
 
logEC50 -6.05 ± 0.13 -6.02 ± 0.35 -6.18 ± 0.42 -6.11 ± 0.20 -5.85 ± 0.12 -5.81 ± 0.09 
anandamide Stim [%] 62 ± 14 84 ± 25 78 ± 8 75 ± 8 286 ± 39*** 93 ± 1 
 
Emax 1.24 ± 0.28 0.81 ± 0.24 1.32 ± 0.14 1.42 ± 0.15 1.61 ± 0.22 1.22 ± 0.01 
 
logEC50 -5.88 ± 0.19 -6.66 ± 0.20** -5.81 ± 0.18 -5.76 ± 0.02 -6.17 ± 0.16* -5.71 ± 0.12 
CP 55,940 Stim [%] 57 ± 8 158 ± 8*** 70 ± 16 76 ± 8 304 ± 9*** 103 ± 15 
 
Emax 1.14 ± 0.16 1.52 ± 0.08 1.19 ± 0.27 1.43 ± 0.15 1.71 ± 0.05 1.36 ± 0.20 
 
logEC50 -7.76 ± 0.12 -7.86 ± 0.08 -7.80 ± 0.04 -7.86 ± 0.13 -7.49 ± 0.05 -7.59 ± 0.26 
WIN 55,212-2 Stim [%] 55 ± 7 94 ± 18* 68 ± 8 78 ± 8 271 ± 16*** 95 ± 5 
 
Emax 1.10 ± 0.14 0.90 ± 0.17 1.15 ± 0.14 1.47 ± 0.15 1.52 ± 0.09 1.25 ± 0.07 
 
logEC50 -7.44 ± 0.18 -7.34 ± 0.12 -7.39 ± 0.29 -7.07 ± 0.08 -6.96 ± 0.09 -7.19 ± 0.06 
AM 251 Stim [%] -64 ± 4 -73 ± 3* -80 ± 2** -62 ± 7 -73 ± 3 -60 ± 3 
 
Emax -1.28 ± 0.08 -0.70 ± 0.03*** -1.36 ± 0.03 -1.17 ± 0.13 -0.41 ± 0.02*** -0.79 ± 0.04** 
 
logIC50 -7.41 ± 0.04 -7.44 ± 0.06 -7.26 ± 0.10 -7.54 ± 0.04 -7.41 ± 0.01 -7.64 ± 0.15 
AM 281 Stim [%] -41 ± 1 -61 ± 4*** -45 ± 2 -38 ± 6 -56 ± 6* -40 ± 1 
 
Emax -0.82 ± 0.02 -0.59 ± 0.04*** -0.76 ± 0.03 -0.72 ± 0.11 -0.31 ± 0.03*** -0.53 ± 0.01* 
logIC50 -7.22 ± 0.18 -7.64 ± 0.09* -7.37 ± 0.07 -7.68 ± 0.16 -7.52 ± 0.14 -7.66 ± 0.26 
 
Steady-state GTPase experiments were performed as described in Materials and Methods. All membranes were additionally transfected with Gβ1γ2. Reaction 
mixtures contained 0.1 µCi [γ-32P]GTP and 100 nM unlabeled GTP in the presence of solvent (basal) and CBR ligands  at various concentrations (1 nM – 10 µM). 
Data shown are the mean values ± SD and represent 3 independent experiments performed in duplicates or triplicates with different membrane preparations. The 
relative agonist-stimulation and inverse agonist-inhibition of GTP hydrolysis (% of basal), were calculated. Emax values represent the stimulation of ligands [10 µM] 
relative to the endogenous agonist 2-AG (defined as 1.00 responses) for each test system. Data were analyzed by nonlinear regression and best fit to sigmoidal 
concentration-response curves. Statistical evaluations were performed to calculate the impact of RGS proteins on GTPase activity in the co-expression and 
fusion system. Results in the presence of RGS proteins were compared to data obtained for CBR + Gαi2 and CBR-Gαi2, respectively, in one-way ANOVA, 
followed by the Dunnett´s multiple comparison test. (significant difference: *p < 0.05, **p < 0.01, ***p < 0.001). 
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Table 3.3: GTPase activities of standard ligands and impact of RGS proteins in Sf9 cell membranes expressing CB2R co-transfected with Gαi2 or CB2R-Gαi2  
 
 
CB2R + Gαi2 CB2R + Gαi2 + RGS4 CB2R + Gαi2 + RGS19 CB2R-Gαi2 CB2R-Gαi2 + RGS4 CB2R-Gαi2 + RGS19 
2-AG Stim [%] 67 ± 15 132 ± 13** 79 ± 16 107 ± 20 197 ± 48* 100 ± 7 
 
Emax 1.00 1.00 1.00 1.00 1.00 1.00 
 
logEC50 -5.29 ± 0.24 -5.73 ± 0.25 -5.72 ± 0.18 -5.72 ± 0.19 -5.55 ± 0.22 -5.33 ± 0.16 
anandamide Stim [%] 54 ± 11 73 ± 13 64 ± 7 146 ± 6 297 ± 67* 163 ± 16 
 
Emax 0.81 ± 0.16 0.55 ± 0.10 0.81 ± 0.09 1.36 ± 0.06 1.51 ± 0.34 1.63 ± 0.16 
 
logEC50 -5.55 ± 0.10 -6.22 ± 0.33* -5.27 ± 0.07 -5.53 ± 0.11 -5.49 ± 0.38 -5.08 ± 0.18 
CP 55,940 Stim [%] 84 ± 9 156 ± 15** 107 ± 16 276 ± 14 393 ± 30* 325 ± 55 
 
Emax 1.25 ± 0.13 1.18 ± 0.11 1.35 ± 0.20 2.58 ± 0.13 1.99 ± 0.15 3.25 ± 0.55 
 
logEC50 -8.05 ± 0.07 -7.94 ± 0.14 -7.96 ± 0.06 -6.98 ± 0.05 -7.04 ± 0.14 -6.60 ± 0.11* 
WIN 55,212-2 Stim [%] 63 ± 13 161 ± 33** 74 ± 10 192 ± 12 255 ± 29 226 ± 36 
 
Emax 0.94 ± 0.19 1.22 ± 0.25 0.94 ± 0.13 1.79 ± 0.11 1.29 ± 0.15 2.26 ± 0.36 
 
logEC50 -8.12 ± 0.07 -8.55 ± 0.24* - 8.09 ± 0.03 -7.28 ± 0.38 -7.34 ± 0.45 -6.69 ± 0.27 
AM 630 Stim [%] -17 ± 8 -48 ± 8** -15 ± 3 -10 ± 2 -24 ± 1*** -10 ± 2 
Emax -0.25 ± 0.12 -0.36 ± 0.06 -0.19 ± 0.04 -0.09 ± 0.02 -0.12 ± 0.01 -0.10 ± 0.02 
logIC50 -6.48 ± 0.65 -5.94 ± 0.33 -7.01 ± 0.46 -6.33 ± 0.11 -6.63 ± 0.32 -6.88 ± 0.31 
 
Steady-state GTPase experiments were performed as described in Materials and Methods. All membranes were additionally transfected with Gβ1γ2. Reaction 
mixtures contained 0.1 µCi [γ-32P]GTP and 100 nM unlabeled GTP in the presence of solvent (basal) and CBR ligands  at various concentrations (1 nM – 10 µM). 
Data shown are the mean values ± SD and represent 3 independent experiments performed in duplicates or triplicates with different membrane preparations. The 
relative agonist-stimulation and inverse agonist-inhibition of GTP hydrolysis (% of basal), were calculated. Emax values represent the stimulation of ligands [10 µM] 
relative to the endogenous agonist 2-AG (defined as 1.00 responses) for each test system. Data were analyzed by nonlinear regression and best fit to sigmoidal 
concentration-response curves. Statistical evaluations were performed to calculate the impact of RGS proteins on GTPase activity in the co-expression and 
fusion system. Results in the presence of RGS proteins were compared to data obtained for CBR + Gαi2 and CBR-Gαi2, respectively, in one-way ANOVA, 
followed by the Dunnett´s multiple comparison test (significant difference: *p < 0.05, **p < 0.01, ***p < 0.001). 
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3.4.4 Influence of fusion on ligands potency and efficacy in the absence and 
presence of RGS proteins 
 The use of Gα
 
co-expression systems is always associated with the problem 
that the expression levels and thus a defined stoichiometry of the signaling partners 
are difficult to control (Gille and Seifert, 2003). This is important since the efficiency of 
GPCR–G protein interaction is dependent on the relative and absolute density of 
these proteins in the plasma membrane (Kenakin, 1997). To compare the CBR co-
expression systems with systems where the Gα subunit is fused to the CBR, we used
 
the
 
ubiquitously expressed Gαi2 subunit (Offermanns, 2003). Figure 3.4 shows 
correlations of potency and efficacy (calculated as stimulation relative to the 
endogenous agonist 2-AG) of ligands at CB1R between the co-expression and fusion 
system in the absence or presence of RGS proteins. As is evident from the slope of 
the linear regression line and the 95% confidence intervals, linear correlations 
between the co-expression and the fusion systems concerning potency and efficacy 
were obtained for CB1R (Figure 3.4).  
 In contrast, the goodness of fit and slope values obtained from the 
comparisons of the CB2R systems (Figure 3.5) indicate that the fusion of the CB2R to 
Gαi2 substantially altered the pharmacological parameters of the ligands. The 
efficacies (Figures 3.5A, C and E) and potencies (Figures. 3.5B, D and F) of ligands 
studied in the absence and presence of RGS proteins clearly differed from each 
other, depending on whether the receptor was fused or co-expressed with Gαi2. The 
most impressive differences were obtained for potency correlations when RGS 
proteins were co-expressed. A r2 value of 0.687 and slope of 0.551 ± 0.215 for RGS4 
(Figure 3.5D) and a r2 value 0.815 and slope of 0.594 ± 0.163 for RGS19 
(Figure 3.5F) indicate a poor correlation between the co-expression and fusion 
protein test system. 
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Figure 3.4: Correlation of potency and efficacy of ligands at the CB1R between the co-
expression and fusion system  
Data of Table 3.2 were analyzed by linear regression. A, C and E, efficacy of ligands at membranes 
co-expressing CB1R, Gαi2 and Gβ1γ2 in the presence or absence of RGS proteins were correlated with 
values obtained from membranes expressing CB1R-Gαi2 and Gβ1γ2 and the respective RGS proteins. 
A, r2 = 0.997; slope = 1.075 ± 0.035. C, r2 = 0.946; slope = 1.073 ± 0.148. E, r2 = 0.986; slope = 0.835 
± 0.057. B, D and F, potency of ligands at membranes co-expressing CB1R, Gαi2 and Gβ1γ2 in the 
presence or absence of RGS proteins were correlated with values evaluated at membranes 
expressing CB1R-Gαi2 and Gβ1γ2 and the respective RGS proteins. B, r2 = 0.902; slope 1.050 ± 0.173. 
D, r2 = 0.940; slope = 1.019 ± 0.129. F, r2 =0.905; slope = 1.122 ± 0.182. Depicted are the linear 
regression lines and the 95% confidence intervals (dotted lines). The diagonal line has a slope of 1 
and represents a theoretical line for identical values in both systems. 1 2-AG, 2 anandamide,  
3 CP 55,940, 4 WIN 55,212-2, 5 AM 251, 6 AM 281  
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Figure 3.5: Correlation of potency and efficacy of ligands at the CB2R between the co-
expression and fusion system  
Data of Table 3.3 were analyzed by linear regression. A, C and E, efficacy of ligands at membranes 
co-expressing CB2R, Gαi2 and Gβ1γ2 in the presence or absence of RGS proteins were correlated with 
values obtained from membranes expressing CB2R-Gαi2 and Gβ1γ2 and the respective RGS proteins. 
A, r2 = 0.967; slope = 1.691 ± 0.220. C, r2 = 0.778; slope = 1.083 ± 0.409. E, r2 = 0.978; slope = 2.130 
± 0.227. B, D and F, potency of ligands at membranes co-expressing CB2R, Gαi2 and Gβ1γ2 in the 
presence or absence of RGS proteins were correlated with values evaluated at membranes 
expressing CB2R-Gαi2 and Gβ1γ2 and the respective RGS proteins. B, r2 = 0.957; slope 0.5567 ± 
0.068. D, r2 = 0.687; slope = 0.551 ± 0.215. F, r2 =0.815; slope = 0.594 ± 0.163. Depicted are the 
linear regression lines and the 95% confidence intervals (dotted lines). The diagonal line has a slope 
of 1 and represents a theoretical line for identical values in both systems. 1 2-AG, 2 anandamide,  
3 CP 55,940, 4 WIN 55,212-2, 5 AM 630 
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3.4.5 Influence of RGS4 on ligands efficacy and potency in the CB2R co-
expression and CB2R fusion system 
 The poor correlations between co-expression and fusion system of CB2R in 
the presence of RGS4 directed us to specifically examine the influence of RGS4 on 
ligand potency and efficacy in the respective systems. As depicted in Figure 3.6, 
r2 values of 0.909 (Figure 3.6A), 0.865 (Figure 3.6B), 0.920 (Figure 3.6C) and 0.966 
(Figure 3.6D) indicated a good correlation of the examined parameters obtained in 
the test systems in the absence and presence of RGS4. However, the 95% 
confidence intervals and standard error values were widely scattered in all cases. 
This pointed to a substantial deviation of the individual ligands from the ideal linear 
regression.  
 
 
Figure 3.6: Influence of RGS4 protein on potency and efficacy of ligands in the co-expression 
and fusion system  
Correlation of efficacy (A and C) and potency (B and D) of ligands evaluated in the absence or 
presence of RGS4 in membranes expression CB2R + Gαi2 (A and B) or CB2R-Gαi2 (C and D). A, r2 = 
0.909; slope = 1.081 ± 0.241. B, r2 = 0.865; slope = 0.888 ± 0.202. C, r2 = 0.920; slope = 0.776 ± 
0.162. D, r2 = 0.966; slope = 1.096 ± 0.118. Depicted are the linear regression lines and the 95% 
confidence intervals (dotted lines). The diagonal line has a slope of 1 and represents a theoretical 
curve for identical values in both systems. 1 2-AG, 2 anandamide, 3 CP 55,940, 4 WIN 55,212-2,  
5 AM 630  
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3.5 Discussion 
In this study the steady-state GTPase assay was used to examine the effects of 
CBR-Gα fusion proteins in comparison to the co-expression system as well as the 
impact of different RGS proteins on the pharmacological properties of standard CBR 
ligands. The GTPase assay and the Sf9 cell membrane expression systems were 
successfully applied to characterize ligands of other Gαi coupled GPCRs such as the 
formyl peptide receptor FPR-26 (Wenzel-Seifert et al., 1998), chemokine receptor 
CXCR4 (Kleemann et al., 2008), histamine H3 receptor (Schnell et al., 2010) and 
histamine H4 receptor (Schneider and Seifert, 2009). As insect cells do not 
endogenously express CBRs (McPartland et al., 2001), infection of Sf9 cells with 
baculoviruses encoding for CBRs offers the advantages to conduct functional studies 
of these GPCRs without interference of endogenous CBRs. Furthermore, 
mammalian-type Gαi proteins are not expressed in Sf9 cells (Quehenberger et al., 
1992; Wenzel-Seifert et al., 1998), so that coupling studies of GPCRs to this 
particular Gα protein can easily be conducted by simultaneous co-transfection with 
the desired Gαi subunit.  
 Previous studies showed that RGS proteins can enhance GPCR-stimulated 
steady-state GTP hydrolysis, facilitating the analysis of partial agonists and inverse 
agonist (Ward and Milligan, 2004). The fact that in our systems only RGS4 but not 
RGS19 exhibits an influence on the pharmacological properties of CBR ligands is 
surprising, since for many GPCRs a similar influence of these GAPs has been 
described. Studies with GPCRs for instance the histamine H1 receptor (Houston et 
al., 2002), histamine H4 receptor (Schneider and Seifert, 2009) and chemokine 
receptor CXCR4 (Kleemann et al., 2008), also expressed in Sf9 insect cells, showed 
that RGS19 strongly enhances agonist-stimulated GTP hydrolysis. The data of our 
present study indicate that the capacity of RGS proteins to regulate GTP hydrolysis 
depends on the specific GPCR and that the GPCR may govern RGS-G protein 
interactions (Abramow-Newerly et al., 2006). It can be argued that the lack of RGS19 
effects is attributable to the fact that RGS19 is a member of the RZ family of RGS 
proteins and does not belong to the R4 family as RGS4 (Ross and Wilkie, 2000). 
Although the polypeptide size of RGS19 is quite similar to RGS4, its N-terminal 
region contains a cysteine string region and a C-terminal PDZ binding motif. The 
scaffold protein GIPC (GAIP-interacting protein) is required for the binding of RGS19 
to the dopamine D2 receptor (Jeanneteau et al., 2004b). As a result, the deficiency of 
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this specific PDZ domain may be responsible for the lack of effect of RGS19 on the 
CBRs.  
In co-expression systems, expression levels and subcellular distribution of the 
signaling partners cannot be exactly controlled, and a fixed stoichiometric ratio of 
GPCR and Gα subunit is difficult to achieve (Gille and Seifert, 2003). Therefore, the 
use of GPCR-Gα fusion proteins, which ensure close proximity of the signaling 
partners and anchor of the Gα subunit in the plasma membrane, offers an elegant 
system to study receptor-G protein interaction under defined conditions (Seifert et al., 
1999; Milligan, 2000). One aim of this study was to examine whether the efficacies 
and potencies of CBR ligands may be altered by the fusion of CBRs to Gα
 
compared 
to their pharmacological behavior in the co-expression system. Three outcomes are 
documented in literature; i. e. decreased, enhanced and equal response of Gαi fusion 
proteins compared to the corresponding co-expression systems. The GTPase assay 
revealed similar concentration-response curves for the 5-HT1A receptor in HEK 293 
cells expressing either the receptor or its fusion protein. In this study, the  
5-HT1A receptor was fused to the PTX-resistant mutant Gαi1Cys351Gly protein (Kellett 
et al., 1999). Data obtained in this system were compared to results obtained for the 
5-HT1A receptor interacting with endogenous Gαi proteins. Interestingly, fusion of the 
5-HT1A receptor to the rat Gαo subunit – also resistant against PTX because of 
mutation of Cys351 to Gly – and expression in COS 7 cells resulted in an 73 ± 2% 
stimulation by the agonist 8-hydroxy-2-(di-n-propylamino)tetralin in the rGαoCys351Gly 
co-expression system versus 55 ± 7% in the fusion system (Dupuis et al., 1999). The 
Edg2 receptor shows an enhanced response for the fusion with rGαi1Cys351Gly 
compared to signals of co-expressed receptor with wild-type rGαi1 and mutant rGαi1, 
respectively (McAllister et al., 2000). In this study, co-expression of receptor with 
wild-type rGαi1 subunit showed the smallest response, indicating that the altered 
responses are, at least in part, due to the mutation of the Cys351 to Gly (McAllister et 
al., 2000).
 
CBRs couple to PTX-sensitive Gi/o proteins (Howlett et al., 2002). Thus, a 
fusion of wild-type Gαi2 to the CBRs was performed. The use of Sf9 cells allowed us 
to avoid cloning of PTX-resistant Gαi2 mutants because of the absence of 
endogenous Gαi (Quehenberger et al., 1992; Wenzel-Seifert et al., 1998). After 
successful expression of the desired proteins in Sf9 cells (Figure 3.1 and Figure 3.2), 
we examined several known ligands of the CBRs in the co-expression and fusion 
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systems and assessed their potency and efficacy to stimulate or inhibit GTPase 
activity. Fusion of Gαi2 to CB1R in the absence of RGS proteins did not significantly 
alter the stimulatory effects of ligands. Only by adding RGS4 to the CB1R expression 
systems higher GTPase activities in the fusion system were elicited compared to the 
co-expression system (Table 3.2). The forced proximity of the Gα subunit to the 
CB2R enhanced the GTPase activation by all ligands. The stimulatory effects of 
ligands in all CB2R-Gαi2 systems were significantly higher than those observed in the 
corresponding receptor-G protein co-expression systems (Table 3.3).  
The higher GTPase stimulations by agonists in the fusion systems, especially 
for CB2R, also affected the efficacies of ligands. A prominent example is anandamide 
in the CB2R systems that behaves like a partial agonist in the co-expression systems 
and switches to the status of a “superagonist” with higher efficacy compared to the 
most abundant endogenous agonist 2-AG in the fusion systems. This may be due to 
a more efficient coupling between receptor and G protein than in a system, where the 
signaling partners were expressed as separate entities.  
The potencies of some ligands were influenced by the fusion of the CB2R to 
the Gαi2 subunit (Figures 3.5B, D and F) and of CB1R in the presence of RGS4 
(Figure 3.4D). The phenomenon of reduced potencies of ligands in fusion protein 
expression systems was observed for the α2A adrenoceptor (Sautel and Milligan, 
1998; McAllister et al., 2000) and the Edg2 receptor (McAllister et al., 2000) and it is 
probably due to physical restrictions inhibiting protein-conformational changes 
(Sautel and Milligan, 1998) and/or compartmentalization of signaling elements within 
specific domains of the plasma membrane (Huang et al., 1997). Also, for the CB2R 
an altered schema of phosphorylation can be discussed as a reason for modulated 
pharmacological parameters of ligands in the comparison fusion – co-expression 
approach. As it is known that agonist treatment of Chinese hamster ovary (CHO) 
cells stably expressing CB2R increases basal phosphorylation of Ser352 (Bouaboula et 
al., 1999), it is conceivable that the ability of a G protein coupled receptor kinase 
(GRK) to phosphorylate the CB2R is altered due to the tethered Gα subunit. The 
relevance of GRKs in Sf9 cells concerning the regulation of GPCR signaling it is still 
unclear (Schneider and Seifert, 2010), but it is likely that a modulated 
phosphorylation can in turn affect efficacy and potency of tested ligands.  
The potential discrepancy of pharmacological parameters between fusion and 
co-expression systems raises the question whether the (CB2)R-Gαi2 system is a 
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usable tool to examine pharmacological parameters of new drugs. The tight tethering 
of the Gα subunits to the membrane and to the receptor itself dictated by the fusion is 
an inherently artificial system. But also, the co-expression system with its accidental 
stoichiometry of receptor-G protein may not mirror a physiological surrounding as it is 
still unclear to how many G proteins a single receptor has access to. Hence, it is 
difficult to evaluate which system is closer to reality and which of the measured 
potencies reflects the drug behavior under physiological condition. Therefore, a 
comparable in-vivo assay in mammalian cells ideally expressing CBR endogenously 
would be required to clarify this issue – a difficult undertaking as recently reported 
(Geiger et al., 2010). However, the use of CBR-Gαi2 fusion proteins offer a highly 
sensitive model system and allow the screening for new CBR ligands with 
characterization of pharmacological parameters at a very proximal point of the 
signaling cascade. With these conditions excellent clues can be provided how the 
compound behaves in-vivo. 
Moreover, it cannot be excluded that RGS proteins may alter ligand potencies 
as well, as it has been described for µ-opioid signaling (Cavalli et al., 2000; Clark et 
al., 2003) and the α2A adrenoceptor (Cavalli et al., 2000) where under the influence of 
RGS proteins the potency of agonists were changed profoundly. Interaction between 
GPCR, RGS and G protein supports the assumption that GPCR function may, 
indeed, be modulated by RGS proteins (Benians et al., 2005; Abramow-Newerly et 
al., 2006). In fact, influences of RGS4 on ligand potency and efficacy were observed 
in the co-expression and fusion system (Figure 3.6) with alterations of slope values 
and widely scattered standard errors and confidence intervals, reflecting a high 
variability in ligand properties. Combination of RGS4 protein with the Gαi2 fusion 
approach augmented the modifications in pharmacological properties of ligands, 
supporting the assumption that the conformational flexibility of the receptors is 
restricted by the spatial proximity of the Gα subunit and the impact of RGS proteins. 
Our data demonstrate that CB2R is affected by these restrictions to a greater extent 
than CB1R. 
The fact that the potency and efficacies of the ligands are not altered similarly 
by the fusion and RGS proteins is indicative for ligand-specific receptor 
conformations. Similarly, at the β2 adrenoceptor (Gether et al., 1995; Seifert et al., 
2001) and the histamine H4 receptor (Schneider et al., 2009), ligands can stabilize 
unique receptor confirmations (Kenakin, 1995) differing in their ability to interact with 
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and activate G proteins. Likely, under the chosen assay conditions some ligands 
stabilize specific GDP/GTP exchange-promoting CBR conformations that are 
influenced by the forced contact to the Gαi2 subunit and the addition of RGS protein. 
Continuing this concept, functional selectivity of CBRs can in turn activate specific 
signaling cascades as it was shown for the CB2R (Shoemaker et al., 2005) which 
offers a great opportunity to develop ligands that selectively manipulate physiological 
functions (Bosier et at., 2010). 
In conclusion, we have shown that RGS4 but not RGS19 behaves as a GAP 
at CBRs in the Gαi2 co-expression and fusion system. We demonstrated that the 
fusion of CBRs to Gαi2 increases the sensitivity of the GTPase assay compared to the 
co-expression system, especially for the CB2R. The fusion system with its extremely 
sensitive readout is therewith excellently suited to study for example structure-
activity-relation of new CBR ligands. The examined alterations of pharmacological 
properties of the CBRs ligands in the different systems seem to be the result of 
complex effects of the fusion approach and RGS protein on ligand-specific receptor 
conformations. In further studies, the impact of other Gi/Go protein subtypes, different 
Gβxγy complexes as well as other RGS proteins on pharmacological properties will 
have to be studied. Ultimately, these studies may result in the development of ligands 
that modulate only a single or few of the multiple functions regulated by CBRs. As a 
result, novel therapeutic uses of CBR ligands with fewer side effects may be 
identified. 
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4 Cannabinoid receptor activity of synthetic 
2,3-disubstituted indole derivatives and several polyacetylenes, 
polyenes and alkamides isolated from Echinacea species  
4.1 Abstract 
Cannabis sativa is among the earliest plants used for medicinal purposes. It 
reached the western medicine in the beginning of the 19th century but its widespread 
use was soon replaced by other analgesic and narcotic medications. The 
identification of the main psychoactive compound of Cannabis sativa, the 
cannabinoid receptors (CBRs) and the endocannabinoids system (ECS) renewed the 
scientific interest. Since the 1990s investigations on the pharmacological potential 
and on modulations of the physiological functions of the ECS are ongoing and effects 
on nausea and emesis caused by cancer chemotherapy, appetite regulation, painful 
conditions and symptoms of multiple sclerosis are demonstrated. For targeting the 
CBRs and to modulate the physiological action of the ECS, new CBRs ligands are 
needed. In this study, a screening of natural compounds isolated from Echinacea 
species and synthetic 2,3-disubstituted indole derivatives was conducted to examine 
their CBR activity. To evaluate the pharmacological properties the steady-state 
GTPase assay was employed. As protein expression system Sf9 cell membranes 
were used and CBR-Gαi2 fusion proteins were co-expressed with Gβ1γ2 and RGS4 
(regulator of G protein signaling 4). The screening of the natural compounds showed 
that the alkamides dodeca-2E,4Z-diene-8,10-diynoic acid isobutylamide, dodeca-
2E,4Z-diene-8,10-diynoic acid 2-methylbutylamide and dodeca-2E,4E,8Z,10E/Z-
tetraenoic acid isobutylamides acted as partial agonists at the CB2R. Polyacetylenes 
and polyenes did not exert functionality at the CBRs. Concerning the synthesized 
indole compounds, derivatives with an ester function at position 3 showed the 
strongest GTPase stimulation and moderate potency at the CB2R. Thereby, 3-(2-
butylindole-3-yl)prop-2-en acid ethyl ester provides a promising base for further 
structure-activity-relation studies and the development of selective CB2R ligands. 
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4.2 Introduction 
 The use of Cannabis sativa for medicinal applications has been reported long 
before the Christian era in China, India, Tibet and Egypt (Touw, 1981; Zuardi, 2006; 
Russo, 2007). Written documents, for example the Shén nóng běn cǎo jīng, the 
world’s oldest pharmacopoeia that was compiled in the first or second century A.D. 
but based on oral traditions from the time of Shén Nóng, already described “great 
hemp” and its psychoactive properties (Aldrich, 1997). Therapeutic indications for the 
use of cannabis included, among others, rheumatic pain, intestinal constipation, 
disorders of the female reproduction system and malaria (Touw, 1981). Also, the 
application to anesthetize patients during surgical operations is reported (Li and Lin, 
1974; Aldrich, 1997). In Western medicine, the use of cannabis was introduced and 
studied in the beginning of the 19th century. In publications of various trials with 
human, administration of Cannabis extract against rheumatism, convulsions and 
mainly for muscular spasms of tetanus and rabies was described (O´Shaughnessy, 
1852). These studies resulted in a widespread use of cannabis throughout the 
Western medicine. With the appearance of various drugs (such as chloral hydrate, 
paraldehyde, barbiturates, opioids and acetylsalicylic acid) with known efficacy for the 
treatment of the main indications of cannabis (Mikuriya, 1969; Zuardi, 2006), the 
release of the Marihuana tax act law 1937 and probably because of difficulties to 
obtain reproducable effects with Cannabis tinctures or extracts, the medicinal 
application of cannabis formulations faded into the background. Only the cannabis 
consumption for hedonistic or recreational purpose increased rapidly since the 
1960s.  
 With the identification of the main psychoactive compound and the publication 
of the partial synthesis of ∆9-THC (Gaoni and Mechoulam, 1964) the scientific 
interest increased and led to the description and cloning of two specific receptors in 
the early 1990´s (Matsuda et al., 1990; Munro et al., 1993) and the discovery of the 
ECS (De Petrocellis et al., 2004). The growing scientific interest led consequently to 
investigations on the therapeutical impact of the ECS and possibilities to influence its 
physiological and pharmacological role. Beneficial clinical results of ∆9-THC on 
nausea/vomiting, appetite, pain as well as on symptoms of multiple sclerosis are 
studied very well (Carlini, 2004). Furthermore, regulation of the ECS in 
cardiovascular, gastrointestinal, and respiratory functions as well as modulation of 
inflammation, cell metabolism and reproduction are main areas of research. 
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Moreover, involvements of the ECS on disorders of the CNS, eyes and 
musculoskeletal apparatus are topics of intense investigations (Pacher et al., 2006).  
To target the CBRs for therapeutic applications, new CBR ligands are needed 
and the search of selective compounds with activity at the CB1R or CB2R are in the 
focus of interest. In this study, a screening of natural and synthetic compounds for 
their CBR activity was conducted using the steady-state GTPase assay. As both 
CBRs couple to pertussis-toxin sensitive Gαi/o proteins (Howlett et al., 2002), 
receptors were fused C-terminally to the N-terminus of the Gαi2 subunit for this 
screening procedure. Sf9 cell membranes were employed to express CBR-Gαi2 
fusion proteins together with Gβ1γ2 and RGS4 proteins. Previous studies revealed 
that the use of fusion proteins in combination with RGS4 resulted in a highly sensitive 
assay that enabled the detection of partial agonists and antagonists (Chapter 3).  
Indole derivates disubstituted at carbons 2 and 3 were screened on their CBR 
activity. In order to mimic the structure of the endocannabinoids 2-arachidonoyl 
glycerol (2-AG) (Sugiura et al., 1995) and anandamide (Devane et al., 1992), the 
unsaturated part of the arachidonic acid was replaced by an indole scaffold. Known 
CBRs ligands with an indole partial structure are comprised in the class of 
aminoalkylindoles, for example the most highly studied, commercially available 
compound of the series, CB1R/CB2R full agonist WIN 55,212-2 (structure see Figure 
4.3; Howlett et al., 2002). 
Previous studies have shown that preparations of Echinacea species 
modulate immune responses (Zhai et al., 2007). Echinacea preparations are among 
the best selling over-the-counter herbal medicines, mainly used for the treatment and 
prevention of the common cold and infections of the upper respiratory tract. It was 
reported that alkamides, the main compounds of the roots of Echinacea purpurea, 
bind to CB2Rs with high affinity (Raduner et al., 2006). Based on these results a 
molecular mode via the CBRs signaling system is discussed for the 
immunomodulatory effects of Echinacea extracts. Therefore, we tested various 
alkamides isolated from Echinacea purpurea, as well as polyacetylenes and polyenes 
isolated from Echinacea pallida concerning their CBR activity.  
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4.3 Materials and methods 
4.3.1 Materials 
CBR fusion proteins were generated as described in Chapter 3. Baculovirus 
encoding Gαi2 was generously provided by Dr. A. G. Gilman (Department of 
Pharmacology, University of Texas, Southwestern Medical Center, Dallas, TX, USA). 
Baculovirus encoding Gβ1γ2 was a kind gift from Dr. P. Gierschik (Department of 
Pharmacology, University of Ulm, Germany). Baculovirus encoding for RGS4 was a 
kind gift from Dr. E. Ross (University of Texas, Southwestern Medical Center, Dallas, 
TX, USA). Phenylmethylsulfonylfluoride and leupeptine hemisulfate were purchased 
from Calbiochem (La Jolla, CA, USA). Benzamidine was from Sigma (99%, St. Louis, 
MO, USA). Adenylyl imidodiphosphate was obtained from Roche (Mannheim, 
Germany). [γ-32P]GTP was synthesized through enzymatic phosphorylation of GDP 
and [32P]orthophosphoric acid (8,000 Ci/mmol, PerkinElmer Life Sciences, Boston, 
MA, USA) as described previously (Walseth and Johnson, 1979).  
All nucleotides, creatine kinase, creatine phosphate and salts (highest purity 
available) were purchased either from Roche (Mannheim, Germany) or Sigma 
(St. Louis, MO, USA). Dimethyl sulfoxide (DMSO) was from Merck (Darmstadt, 
Germany). Tris base was purchased from USB (Cleveland, OH, USA).  
Synthesized indole derivatives (for structures and names see Table 4.1) were 
kindly provided by Mehrnaz Pirasteh (Department of Pharmaceutical and Medicinal 
Chemistry, Group of Prof. Bernhard Wünsch, Westfälische Wilhelms University 
Münster, Germany). Polyacetylenes, polyenes (Table 4.2) and alkamides (Table 4.3) 
were a kind gift from Elisabeth Feizlmayr (Institute of Pharmaceutical Sciences, 
Group of Prof. Rudolf Bauer, Karl Franzens-University Graz, Austria).  
The 10 mM stock solutions of these compounds were prepared with 
100% DMSO and dilutions of all ligands were prepared with 30% DMSO. Final assay 
concentration of DMSO was always lower than 3%. 
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Table 4.1: Structures of investigated indole derivatives 
N
H
R1
R2
 
 
compound R1 R2 name 
1 CH3
 
CH3O
O
 
3-(2-butylindole-3-yl) 
prop-2-en acid  
ethyl ester 
2 
 
CH3
 
CH3O
O
 
3-(2-pentylindole-3-yl) 
prop-2-en acid 
 ethyl ester 
3 CH3
 
OHN
H
O
 
3-(2-butylindole-3-yl)- 
N-(2-hydroxy ethyl) 
propanamide 
4 CH3
 
OHN
H
O
 
3-(2-pentylindole-3-yl)- 
N-(2-hydroxy ethyl) 
propanamide 
5 CH3
 
OHN
H
O
 
3-(2-butylindole-3-yl)- 
N-(2-hydroxy ethyl)  
prop-2-enamide 
6 CH3
 
OHN
H
O
 
3-(2-pentylindole-3-yl)- 
N-(2-hydroxy ethyl)  
prop-2-enamide 
7 CH3
 
OHN
H
O CH3
 
3-(2-butylindole-3-yl)- 
N-(1R-methyl 2- 
hydroxy ethyl)  
prop-2-enamide 
8 CH3
 
OHN
H
O CH3
 
3-(2-pentylindole-3-yl)- 
N-(1R-methyl 2- 
hydroxy ethyl)  
prop-2-enamide 
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Table 4.2: Structures of tested ketoalkenes isolated from Echinacea pallida 
compound structure name 
9 
OHO
 
8-hydroxy-
tetradeca-9E-ene-11,13-
diyn-2-one 
10 
OHO
 
8-hydroxy-
pentadeca-9E-ene-11,13-
diyn-2-one 
11 
O
 
tetradeca-8Z-ene-
11,13-diyn-2-one 
12 
O
 
pentadeca-8Z-ene-
11,13-diyn-2-one 
13 
O
 
pentadeca-8Z,13Z-
diene-11-yn-2-one 
 
14 
O
 
pentadeca-8Z,11Z-
diene-2-one 
 
15 
O
 
pentadeca-8Z-ene-
2-one 
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Table 4.3: Structures of tested alkamides isolated from Echinacea purpurea 
compound structure name 
16 
N
H
O
 
 
N
H
O
 
undeca-2E/Z,4Z/E-diene-
8,10-diynoic acid 
isobutylamides 
17 N
H
O
 
dodeca-2E,4Z-diene-
8,10-diynoic acid  
isobutylamide 
18 N
H
O
 
dodeca-2E,4Z-diene-
8,10-diynoic acid 2-
methylbutylamide 
19 
N
H
O
 
N
H
O
 
dodeca-2E,4E,8Z,10E/Z-
tetraenoic acid  
isobutylamides 
20 N
H
O
 
dodeca-2E,4E-dienoic 
acid isobutylamide 
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4.3.2 Methods 
4.3.2.1 Generation of recombinant baculoviruses and membrane preparation of 
transfected Sf9 cells 
Sf9 cells, derived from Spodoptera frugiperda pupal ovarian tissue, were used 
for baculovirus expression. Sf9 cells were cultured in Erlenmeyer flasks at 28°C 
under rotation at 125 rpm in SF 900 II medium (Invitrogen, Carlsbad, CA, USA), 
supplemented with fetal calf serum (Pan-Biotech, Aidenbach, Germany) to 5% (v/v) 
and gentamicin sulfate (BioWhittaker, Walkersville, MD, USA) to 0.1 mg/ml. 
Recombinant baculoviruses encoding FLAG- and hexahistidine-tagged CB1R-Gαi2 
and CB2R-Gαi2, Gβ1γ2 and RGS4 protein were generated in Sf9 insect cells using the 
BaculoGOLD transfection kit (BD PharMingen, San Diego, CA) according to the 
manufacturer´s instructions. After initial transfection, high-titer virus stocks were 
generated by two sequential virus amplifications. 
For transfection, cells were seeded in Erlenmeyer flasks (cell density 3.0 x 106 
cells/ml) and infected with a 1:100 dilution of high-titer baculovirus stocks. Cells were 
cultured for 48 h and Sf9 membranes were prepared as described previously (Seifert 
et al., 1998). Briefly, cells were washed once by centrifugating for 10 min at 170 x g, 
discarding the supernatant and resuspending the cell pellet in PBS buffer. After 
repeating the centrifugation step, the supernatant fluid was discarded and the pellet 
was suspended in lysis buffer (containing 10 mM Tris/HCl pH 7.4, 1 mM EDTA, 
0.2 mM phenylmethylsulfonylfluoride, 10 µg/ml benzamidine and 10 µg/ml leupeptin) 
and homogenized in a Dounce homogenizer with 25 strokes. After centrifugation at 
40 x g for 5 min the pellet contained the nuclei and unbroken cells and the 
supernatant contained the membranes. Therefore, the supernatant fluid was carefully 
transferred to a plastic tube and spun down by 38,500 x g for 20 min. The pellet 
containing the membranes was resuspended in lysis buffer and again centrifuged as 
described above. The resultant membrane pellet was resuspended in buffer 
containing 75 mM Tris/HCl, pH 7.4, 1 mM EDTA, and 12.5 mM MgCl2, homogenized 
by a syringe with 20 strokes and stored in aliquots at -80°C. Protein concentrations 
were determined using the DC protein assay kit (Bio-Rad, Hercules, CA) according to 
the instructions of the manufacturer. Membranes used in the assays were analyzed 
by SDS page and immunoblotting with specific antibodies against FLAG-tagged 
CBRs, G protein subunits and RGS protein to ensure correct transfection (see 
Chapter 3). 
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4.3.2.2 Steady-state GTPase assay 
The GTPase assay was performed as described previously (Preuss et al., 
2007). Briefly, membranes were thawed, sedimented by centrifugation at 18,000 x g 
for 10 min at 4°C, and carefully resuspended in 10 mM Tris/HCl, pH 7.4. Assay tubes 
contained membranes (5 µg of protein/tube), 1.0 mM MgCl2, 0.1 mM EDTA, 0.1 mM 
ATP, 100 nM GTP, 0.1 mM adenylyl imidodiphosphate, 5 mM creatine phosphate, 
40 µg of creatine kinase, 0.2% (w/v) BSA (to prevent binding of protein or ligand to 
the polystyrol tubes) in 50 mM Tris/HCl, pH 7.4, and test compounds at various 
concentrations. Reaction mixtures (80 µl) were incubated for 2 min at 25°C prior to 
addition of 20 µl of [γ-32P]GTP (0.1 µCi/tube). All stock and work dilutions of  
[γ-32P]GTP were prepared in 20 mM Tris/HCl, pH 7.4. Reactions were conducted for 
10 min at 25°C and terminated by the addition of 90 0 µl of slurry consisting of 5% 
(w/v) activated charcoal and 50 mM NaH2PO4, pH 2.0. Charcoal absorbs nucleotides 
but not 32Pi. Charcoal-quenched reaction mixtures were centrifuged for 7 min at room 
temperature at 15,000 x g. 600 µl supernatant fluid of reaction mixtures was removed 
and 32Pi was determined by Čerenkov radiation in 3 ml water. Enzyme activities were 
corrected for spontaneous degradation of [γ-32P]GTP. Spontaneous [γ-32P]GTP 
degradation was determined in tubes containing all of the above described 
components plus a high concentration of unlabeled GTP (1 mM) that, by competition 
with [γ-32P]GTP, prevents [γ-32P]GTP hydrolysis by enzymatic activities present in Sf9 
membranes. Spontaneous [γ-32P]GTP degradation amounted to <1% of the total 
amount of radioactivity added. The experimental conditions chosen ensured that not 
more than 20% of the total amount of [γ-32P]GTP added was converted to 32Pi. 
Neutral antagonism was determined in the presence of 30 nM CP 55,940. 
4.3.2.3 Calculations and statistics 
Data are expressed as means ± SD and represent a minimum of 2 
independent experiments, each performed in triplicates. Compounds that modulated 
GTPase activity with more than +15% or -15% above basal activity were examined in 
concentration-response experiments. Statistical evaluations and curve fittings were 
calculated using the GraphPad Prism 4 software (La Jolla, CA) and the Microsoft 
Excel 2007 software.  
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4.4 Results 
4.4.1 GTPase activity of synthesized indole derivatives 
 The potencies and efficacies of indole derivatives (Table 4.1) were examined 
in the GTPase assay with Sf9 membranes expressing CB1R-Gαi2 or CB2R-Gαi2, 
always together with Gβ1γ2 and RGS4. As shown in Figure 4.1, compounds 1, 2 and 
4 altered basal GTPase activity of the CB2R whereas the basal GTPase activity of 
the CB1R is not markedly enhanced or reduced. All compounds without activity in the 
normal mode were additionally tested in the antagonist mode in the presence of 
CP 55,940. Again, no effect was detected (data not shown). 
 Compound 1 showed the highest GTPase stimulation with 126 ± 16% 
stimulation above basal GTPase activity at the CB2R. Evaluation of concentration-
response curves revealed a logEC50 value in a low micromolar range (-5.28 ± 0.15) 
for this substance showing the strongest pharmacological properties of the tested 
indole derivatives (Table 4.4). Also compounds 2 and 4 showed effects at the CB2R 
with modulation of GTPase activity of 87 ± 18% and 42 ± 6%, respectively. For 2 a 
logEC50 value of -4.79 ± 0.10 and for 4 a logEC50 value of -4.67 ± 0.25 was evaluated 
(Table 4.4). 
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Figure 4.1: Efficacy of indole derivatives analyzed in the GTPase assay with Sf9 membranes 
GTPase assays were conducted as described in Materials and Methods with Sf9 membranes 
expressing CB1R-Gαi2 or CB2R-Gαi2 together with Gβ1γ2 and RGS4. Reaction mixtures contained 
0.1 µCi [γ-32P]GTP and 100 nM unlabeled GTP in the presence of solvent (basal) and test compounds 
(30 µM). Data are given as mean values ± SD and represent at least 2 independent experiments 
performed in duplicates or triplicates with different membrane preparations. 
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4.4.2 GTPase activity of compounds isolated from Echinacea root extracts 
 To examine the CBR activity of natural compounds, we tested several 
polyacetylenes and polyenes isolated from Echinacea pallida (Nutt.) Nutt. (Table 4.2) 
as well as several alkamides isolated from Echinacea purpurea L. (Table 4.3) in the 
GTPase assay. The percental change of basal GTPase activity assessed with 30 µM 
test substance is depicted in Figure 4.2. While the polyacetylenes and polyenes did 
not alter the basal activity, compounds 17, 18 and 19 acted as agonists at the CB2R. 
The strongest GTPase stimulations were evaluated for 18 with 136 ± 14% stimulation 
and 17 with a stimulation of 81 ± 5%. The diastereomers 19, the main alkamides in 
Echinacea purpurea, altered GTPase activity positively with 64 ± 10%. Also, for these 
ligands concentration-response curves were mapped and pharmacological 
parameters calculated (Table 4.4). All compounds without activity in the normal mode 
were additionally tested in the antagonist mode in the presence of CP 55,940. Again, 
no effect was detected (data not shown). 
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Figure 4.2: Efficacy of polyacetylenes, polyene and alkamides analyzed in the GTPase assay 
with Sf9 membranes 
GTPase assays were conducted as described in Materials and Methods with Sf9 membranes 
expressing CB1R-Gαi2 or CB2R-Gαi2 together with Gβ1γ2 and RGS4. Reaction mixtures contained 
0.1 µCi [γ-32P]GTP and 100 nM unlabeled GTP in the presence of solvent (basal) and test compounds 
(30 µM). Data are given as mean values ± SD and represent at least 2 independent experiments 
performed in duplicates or triplicates with different membrane preparations. 
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Table 4.4: GTPase activities of compounds in Sf9 cell membranes expressing CB2R-Gαi2, Gβ1γ2 
and RGS4 
ligand GTPase stimulation % Emax logEC50 
2-AG 197 ± 48 1.00 -5.55 ± 0.22 
1 126 ± 16 0.64 ± 0.08 -5.28 ± 0.15 
2 87 ± 18 0.44 ± 0.04 -4.79 ± 0.10 
4 42 ± 6 0.21 ± 0.03 -4.67 ± 0.25 
17 81 ± 5 0.41 ± 0.03 -4.86 ± 0.03 
18 136 ± 14 0.69 ± 0.07 -5.51 ± 0.10 
19 64 ± 10 0.32 ± 0.05 -4.86 ± 0.04 
 
Steady-state GTPase experiments were performed as described in Materials and Methods. Reaction 
mixtures contained 0.1 µCi [γ-32P]GTP and 100 nM unlabeled GTP in the presence of solvent (basal) 
and CBR ligands at various concentrations (10 nM – 30 µM). The relative agonist-stimulation of GTP 
hydrolysis was calculated in percent above basal. Data shown are the mean values ± SD and 
represent at least 3 independent experiments performed in triplicates with different membrane 
preparations. Emax values represent the stimulation of ligand relative to the endogenous agonist 2-AG 
(defined as 1.00 response). Data were analyzed by nonlinear regression and fit to sigmoidal 
concentration-response curves.  
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4.5 Discussion 
In the current study, the GTPase assay was used to examine the activity of 
various synthetic and natural compounds at the CBRs. The GTPase assay is a 
reliable functional test system that is – beneath [35S]GTPγS binding assays, 
competition binding assays with a radiolabeled ligand, adenylyl cyclase assays and 
Ca2+ determination – well established for the assessment of the pharmacological 
properties of GPCR ligands (Wieland and Seifert, 2005; Geiger et al., 2010). 
Sf9 cell membranes were used as protein expression system and the 
employment of CBR-Gαi2 fusion proteins in combination with RGS4 guaranteed a 
highly sensitive test system (see Chapter 3). The use of the fusion approach ensures 
a defined 1:1 stoichiometry and a spatial proximity of the signaling partners (Seifert et 
al., 1999), which markedly enhanced the sensitivity of the CBR GTPase assay. 
Furthermore, addition of RGS4 protein was auxiliary for an increased maximal 
stimulatory effect of standard ligands at the CBRs (Geiger et al., 2010; Chapter 3). 
These prerequisites provide the base for the detection of even partial agonists and 
inverse agonists.  
All tested synthetic compounds were indole derivatives. Position 2 was 
substituted with n-butyl or n-pentyl chains and various substituents with ester or 
amide function were placed at position 3 (Table 4.1). These 2,3-disubstituted indole 
derivatives were synthesized to mimic the structure of the endocannabinoids 
anandamide and 2-AG (Mackie, 2006). Moreover, there are well known CBRs ligands 
like WIN 55,212-2, an agonist at both CBRs, and AM 630, a ligand with neutral 
antagonistic properties at the CB2R, that comprise this indole scaffold (Pertwee, 
1999) showing remarkable potency and efficacy in the GTPase assay (Chapter 3). 
Structure-activity-relation (SAR) studies of aminoalkylindoles, a large group of 
synthetic cannabinoids with WIN 55,212-2 (Figure 4.3) as prominent member, were 
conducted previously. Results from these SAR studies showed that shortening of the 
side chain of the indole nitrogen may produce agonists with high affinity to the CB2R 
– like JWH-018 and JWH-015 (Figure 4.3; Showalter et al., 1996). Other SARs with 
different indole series propose the use of naphthoyl or 2,3-dihalogenated benzoyl 
residues at the indole nitrogen. This led to the discovery of L-768,242 (Gallant et al., 
1996), an indole derivative that displayed significant selectivity for the CB2R. As 
depicted in Figure 4.3 all these compounds contain a methyl group 
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Figure 4.3: Structures of four indole derivatives with CBR agonistic properties 
 
at position 2 and an alkyl morpholino or a naphthoyl methanon moiety at position 3. 
Our data showed that displacement of the indole nitrogen substituent in combination 
with longer alkyl chains in position 2 also results in significant selectivity for the CB2R.  
While all synthesized compounds showed no effects at the CB1R, compounds 
1, 2 and 4 exhibited properties of partial agonists at the CB2R compared to the most 
abundant endogenous agonist 2-AG (Emax set as 1.00; Table 4.4). Substituents with 
an ester function at position 3 showed greater efficacies than substituents with amide 
function. For the ester compounds 1 and 2, Emax values of 0.64 ± 0.08 and 0.44 ± 
0.04, respectively were calculated. Compound 4, containing an amide function, 
displays an Emax value of 0.21 ± 0.03. It can be assumed that the 2-hydroxy ethyl 
amides at position 3 are too hydrophilic for the interaction with the CBR binding site. 
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Furthermore n-butyl chains (1) were outmatching n-pentyl (2) substituents at 
position 2. 
To conclude, an ethyl ester function in combination with lipophilic alkyl 
moieties seems to be a solid base to examine SAR for CB2R selective compounds. 
The investigated natural compounds, all isolated from Echinacea species, are 
in the focus of research because the mechanism of action of Echinacea is still 
unclear. However, a modulation of innate and adaptive immune response is reported 
(Zhai et al., 2007). Since it was found that the endocannabinoid system is a target of 
alkamides (Gertsch et al., 2004; Woelkart et al., 2005; Raduner et al., 2006), these 
lipophilic compounds of the roots of Echinacea purpurea and Echinacea pallida var. 
angustifolia are discussed as key substances for the immunomodulatory effects of 
Echinacea preparations. Hence, it is surprising that only three of the tested alkamides 
showed activity at the CB2R. Compared to 2-AG, compounds 17, 18 and 19 belong to 
the field of partial CB2R agonists with efficacies of 0.41 ± 0.03 (17), 0.69 ± 0.07 (18) 
and 0.32 ± 0.05 for (19). For compound 18, the strongest CB2R-activator of the 
tested alkamides, a logEC50 of -5.51 ± 0.10 was assessed, showing similar potency 
compared to 2-AG with a logEC50 value of -5.55 ± 0.22. The lacking activity of 
compound 20 is astonishing since Raduner measured displacement in competition 
binding with radiolabeled ligand and effects on the Ca2+ levels caused by 20 in HL60 
cells (Raduner et al., 2006). Tested in the co-expression system (Chapter 2) and also 
in the higher sensitive fusion protein system no effects at CBRs were measurable. 
Possible explanations, as interactions with specific G protein subunits, are discussed 
in Chapter 2.  
In contrast to the alkamides, the polyacetylenes and polyenes isolated from 
Echinacea pallida root extracts, did not show any activity at the CBRs. This is in 
accordance with Egger et al., (2008) who examined ketoalkenes and non-natural 
conjugated analogues on their activity at CBRs. In this study, only the ketoanalogue 
of anandamide and the dodeca-8Z-10-in-11phenyl-2-one were found to have 
agonistic properties at CBRs. These results lead to the conclusion that Echinacea 
pallida preparations, which almost lack of alkamides (Binns et al., 2002), do not 
conduct their immunomodulatory action via the CBRs.  
All compounds that revealed lacking effects at the CBRs were tested in the 
antagonist mode in the presence of 30 nM CP 55,940 to exclude the unlikely 
occurrence of a neutral antagonist (Kenakin, 2004). Likewise, no alteration of the 
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basal GTPase activity was measurable indicating that these substances do not 
interact with the CBRs (data not shown). 
In conclusion, among the tested alkamides and polyacetylenes, only the 
alkamides dodeca-2E,4Z-diene-8,10-diynoic acid isobutylamide, dodeca-2E,4Z-
diene-8,10-diynoic acid 2-methylbutylamide and dodeca-2E,4E,8Z,10E/Z-tetraenoic 
acid isobutylamides showed measurable activity with selectivity at the CB2R. 
Furthermore, new 2,3-disubstituted indole derivatives with activity at the CB2R were 
found. Thereby, the 3-(2-butylindole-3-yl)prop-2-en acid ethyl ester showed the 
strongest effect and provides a promising basis for the development of potent and 
selective CB2R ligands.  
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5 Conclusion 
So far two human cannabinoid receptors (hCBRs) have been identified, both 
belonging to the family of G protein coupled receptors (GPCRs): the hCB1R mainly 
located in the brain and the hCB2R predominantly located in the periphery on 
immune cells. Because of their involvement in many physiological functions, such as 
movement, metabolic regulation, host defense, analgesia and memory, there is still a 
great interest for targeting CBRs for therapeutic applications. 
The aim of this thesis was the establishment of a highly sensitive assay system 
that is suitable to analyze CBR pharmacology and to screen ligands concerning their 
CBR activity and their pharmacological profile. Therefore, we established the steady-
state [γ-32P]-GTPase assay, a functional, sensitive and reliable approach to study 
GPCRs with a read out at a very proximal point of the signal cascade. In native 
systems, this in-vitro assay showed a very low sensitivity. In rat cerebellum 
membrane only a weak stimulation of GTPase activity was measurable. The use of 
membranes of CBR transfected HEK 293 cells did not lead to a successful outcome 
as no change of GTPase activity caused by a ligand was detectable. These results 
directed us to employ Spodoptera frugiperda (Sf9) cell membranes as expression 
system. Here, the co-expression of CBRs, Gα subunit and the Gβγ heterodimer 
greatly improved the sensitivity of the assay.  
As the efficacy of receptor-G protein interaction is highly influenced by the 
expression levels and density of these proteins in the membrane, we examined the 
impact of CBR-Gα fusion proteins on pharmacological properties of known CBR 
ligands. With the defined 1:1 stoichiometry and the forced anchor of the signaling 
partners in the membrane, the sensitivity of the GTPase assay was dramatically 
increased. Influences of regulators of G protein signaling (RGS) proteins RGS4 and 
RGS19 on GTPase activity in the co-expression and fusion system were examined. 
The results revealed that RGS4 in contrast to RGS19 behaves as a GTPase 
activating protein (GAP) for CBRs.  
Comparing pharmacological properties of known CBR ligands evaluated in the 
co-expression and fusion systems in the absence or presence of RGS4 and RGS19, 
altered potencies and efficacies became apparent, especially in the CB2R test 
systems. These data suggests that ligands stabilized specific GDP/GTP exchange-
promoting receptor conformations that are influenced by the forced contact to the 
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Gαi2 subunit and the addition of RGS protein. This phenomenon is indicative for the 
concept of ligand-specific receptor conformation. 
For ligand screening procedures and to evaluate pharmacological parameters 
of new CBRs ligands, we used Sf9 cell membranes expressing CBR-Gα fusion 
proteins, the Gβγ-heterodimer and RGS4 as this constellation offers the highest 
sensitivity among the tested protein combinations. We examined various alkamides, 
polyacetylenes and polyenes isolated from Echinacea species as well as synthesized 
indole derivatives. From the natural compounds several alkamides showed 
measurable activity in a CB2R selective manner. In contrast to the alkamides, 
polyacetylenes and polyenes did not show any effect, suggesting that they do not 
exert their immunomodulatory effect via the CBRs. Furthermore, new  
2,3-disubstituted indole derivatives with activity at the CB2R were found. Thereby, the 
3-(2-butylindole-3-yl)prop-2-en acid ethyl ester showed the strongest effect and 
provides a promising basis for the development of potent and selective CB2R ligands. 
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6 Appendix 
List of abbreviations  
2-AG   2-arachidonoyl glycerol 
AM 251  N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-1H-pyrazole-3-carboxamide 
AM 281  1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-mor-
pholinyl-1H-pyrazole-3-carboxamide 
AM 630 (6-iodo-2-methyl-1-[2-4(morpholinyl)-ethyl]-[1H-indol-3-yl]-(4-
methoxyphenyl)methanone) 
ATP adenosine 5`-triphosphate 
bp base pair(s) 
BSA bovine serum albumin 
cAMP 3´,5´-adenosine monophosphate  
cDNA copy DNA 
CNS central nervous system 
CP 55,940 [(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-
hydroxypropyl)cyclohexanol] 
CB1R human cannabinoid receptor subtype 1 
CB2R human cannabinoid receptor subtype 2  
C-terminus carboxy-terminus 
DAG 1,2-diacylglycerol 
DMSO dimethyl sulfoxide 
EC50 agonist concentration which induces 50% of the maximum effect 
ECS endocannabinoid system 
EDTA ethylenediaminetetraacetic acid (Ca2+-chelator) 
Emax efficacy (maximal response) 
FLAG octapeptide epitope for the labeling of proteins  
Gαi α subunit of G proteins that inhibits adenylyl cyclase 
Gαq  α subunit of G proteins that activates phospholipase C 
Gαs  α subunit of G proteins that stimulates adenylyl cyclase 
GAP GTPase activating protein 
Gβγ βγ subunit of a heterotrimeric G protein 
GDP guanosine 5´-diphosphate 
GIT gastrointestinal tract 
GPCR  G protein coupled receptor 
GTP   guanosine 5´-triphosphate 
GTPγS  guanosine 5´-[γ-thio]triphosphate 
h   hour(s) 
5-HT 5-hydroxy tryptophan 
His6 hexahistidin tag 
IC50 antagonist concentration which suppresses 50% of an agonist 
induced effect 
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IP3   inositoltrisphosphate 
kDa   kilodalton 
MAPK   mitogen-acitivated protein kinase 
N-terminus  amino-terminus 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
Pi   inorganic phosphate 
PIP2   phosphatidylinositolbisphosphate 
PLC   phospholipase C 
r2   correlation coefficient 
rimonabant N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-1H-pyrazole-3-carboxamide 
RGS   Regulator of G protein signaling 
rpm   revolutions per minute 
SAR structure-activity-relation 
SD standard deviation 
SDS-PAGE  sodiumdodecylsulfate polyacrylamide gel electrophoresis 
Sf9   insect cell line of Spodoptera frugiperda  
∆9-THC  ∆9-tetrahydrocannabinol 
TM   transmembrane  
Tris   tris(hydroxymethyl)aminomethan 
WIN 55,212-2 (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyr-
rolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmetha-none 
mesylate 
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